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SUMMARY 
 
The immune system is involved in the course of numerous diseases of the central 
nervous system (CNS). On the one hand, beneficial immune responses play an 
important role in the control of infectious agents. On the other hand, detrimental 
immune responses can be misdirected against structures of the body’s self. Multiple 
Sclerosis (MS), for example, is an autoimmune disorder of the CNS involving immune 
responses directed against CNS self-antigens. A common characteristic of MS and 
infectious CNS diseases like neuroborreliosis (NB) is the presence of an antigen 
driven immune response in the cerebrospinal fluid (CSF). This is exemplified by the 
presence of clonally expanded B cells and plasma cells (cePC) and their presumed 
products, oligoclonal immunoglobulins (Ig). These can be visualized as oligoclonal 
bands (OCB) on isoelectric focussing gels. While it is known that in CNS infections at 
least some of the OCB are directed against the causative infectious agent, the 
specificity and disease relevance of OCB in chronic inflammatory autoimmune 
diseases of the CNS, such as MS, remain unknown.  
The goal of this work was to dissect the antigen-specific, humoral immune response 
in the CSF down to a single cell level in order to investigate its potential role played in 
inflammatory disorders of the CNS such as NB or MS.  
Individual, CD138+, FACS sorted CSF plasma cells were used as the basis for the 
present studies. Starting with single cell RT-PCR of Ig genes (heavy and light chains) 
of CSF plasma cells from a patient with NB we identified expanded plasma cell 
clones. The antigen specificity of their secreted antibodies was resurrected by 
recombinant expression of correctly paired Ig heavy and light chain genes as 
monoclonal antibodies (mAb). As expected, we found specificity for the causative 
infectious agent Borrelia burgdorferi (Bb) among the cePC derived mAb. Interestingly 
however, we also obtained one mAb specific for human CNS myelin, without 
detectable cross-reactivity with Bb antigens, from an independent cePC of the same 
patient. 
These findings indicate that in NB mechanisms may be at play that induce distinct 
antigen driven immune responses specific for pathogen and self-antigens 
independent from “molecular mimicry”. Based on these results we conclude that the 
applied experimental strategy faithfully reproduces antigen specificities as found in 
CNS inflammations and that the resulting mAbs can be used for the analysis of 
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potential antigenic targets. Because the immunopathological relevance of cePC in 
the CSF of MS patients remains unknown, we moved on to produce mAbs from these 
cePCs. Immunofluorescence experiments indicate CNS reactivity of these mAbs. 
However, their cognate antigens have not been conclusively identified up to now. 
Future work is aimed at unraveling their antigen specificity and is expected to further 
elucidate underlying disease mechanisms in MS. 
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ZUSAMMENFASSUNG 
 
Das Immunsystem spielt bei verschiedenen Krankheiten des zentralen 
Nervensystems (ZNS) eine wichtige Rolle. Einerseits bekämpft es infektiöse Erreger, 
anderseits kann irrtümlicherweise auch eine schädigende Immunreaktion gegen 
körpereigene Strukturen entstehen. Die Multiple Sklerose (MS) ist eine 
Autoimmunerkrankung, bei der das ZNS angegriffen wird. Sowohl bei der MS als 
auch bei infektiösen Erkrankungen des ZNS, wie zum Beispiel der Neuroborreliose 
(NB), können im Liquor cerebrospinalis Spuren einer Antigen-induzierten 
Immunantwort nachgewiesen werden. Dazu gehören klonal expandierte B- und 
Plasmazellen sowie oligoklonale Immunoglobuline, die auf isoelektrisch fokussierten 
Gelen als oligoklonale Banden (OKB) dargestellt werden können. Wie bereits gezeigt 
werden konnte, sind bei chronischen ZNS Infektionen ein Teil der OKB gegen den 
zugrunde liegenden Erreger gerichtet. Jedoch ist die Spezifität und 
Krankheitsrelevanz von OKB bei chronischen Entzündungen des ZNS, wie bei der 
MS, nach wie vor unbekannt. 
Das Ziel dieser Arbeit war, die bei der NB und MS im ZNS stattfindende Antigen-
induzierte, humorale Immunantwort, bis auf die Ebene der von Plasmazellklonen 
produzierten Antikörpern zu "zerlegen". Hierfür wurde ein System zur Herstellung 
rekombinanter Antikörper etabliert, deren Antigenspezifität und Affinität exakt den 
Antikörpern entspricht, welche von klonal expandierten Plasmazellen im Liquor von 
Patienten produziert werden.  
Einzelne, CD138+, FACS sortierte Plasmazellen aus dem Liquor waren die Basis der 
hier präsentierten Studien. RT-PCR der Immunoglobulingene (IgG, schwere und 
leichte Ketten) einzelner Plasmazellen ermöglichte die Identifizierung expandierter 
Plasmazellklone. Durch die rekombinante Produktion monoklonaler Antikörper (mAk) 
mit korrekt gepaarten schweren und leichten Immunoglobulinketten, wurde die 
ursprüngliche Antigenspezifität rekonstruiert.  
Zunächst wurden verschiedene mAk klonal expandierter Liquor-Plasmazellen eines 
Patienten mit NB hergestellt. Wie erwartet, fand sich unter diesen ein Antikörper mit 
Spezifität für den zugrunde liegenden infektiösen Erreger Borrelia burgdorferi (Bb).  
Interessanterweise zeigte jedoch ein mAk eines anderen Plasmazellklons Spezifität 
für ZNS Myelin, ohne dass dieser Antikörper mit Bb Antigenen kreuzreagierte. 
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Diese Ergebnisse weisen darauf hin, dass in NB Mechanismen eine Rolle spielen, 
welche unabhängig von “molecular mimicry“ eine Antigen-induzierte Immunantwort 
sowohl gegen den Erreger als auch gegen Autoantigene hervorrufen. Da diese 
Resultate zudem die Anwendbarkeit der hier präsentierten experimentellen Strategie 
eindeutig nachweisen, wurde das Augenmerk zusätzlich auf Plasmazellen von MS 
Patienten gerichtet. Dies insbesondere deshalb, da die Ziel-Antigene und 
immunopathologische Relevanz der im Liquor zu findenden Plasmazellen von MS 
Patienten bis anhin unbekannt sind. Erste Resultate zeigen, dass mAk, welche von 
Plasmazell-Klonen aus dem Liquor von MS Patienten rekonstruiert wurden, in 
Immunofluoreszenzfärbungen eine ZNS Reaktivität aufweisen. Zukünftige Arbeit 
beabsichtigt die Identifizierung der Antigene und könnte dadurch helfen, die der MS 
zugrunde liegenden Krankheitsmechanismen besser zu verstehen.  
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1 INTRODUCTION 
 
1.1 The humoral immune response in central nervous system 
inflammations  
1.1.1 Introduction 
 
Inflammation is the first response of the immune system to danger signals evoked by 
infection or irritation. It is manifested by invasion of circulating immune cells into the 
inflamed tissue and induction or activation of inflammatory mediators.  
For a long time, the central nervous system (CNS) was considered to be "immune 
privileged" in the sense of not contributing to inflammation. This dogma is no longer 
tenable. The CNS does exhibit features that suggest active involvement in 
inflammation, and in response to injury, infection or disease, resident CNS cells can 
generate inflammatory mediators and recruit immune cells.  
Two major populations of lymphocytes - B and T cells - are involved in the adaptive 
and specific immune response. They are responsible for the humoral and cell-
mediated branches of the immune system. The present studies focuses on the 
humoral immune response produced by B cells. The inflammatory response has a 
clear benefit in infectious states, when activated in a regular manner for a defined 
period of time. However, sustained, excessive or inappropriate inflammation can be a 
major cause for the damage of tissue in several diseases, including Multiple Sclerosis 
(MS) and neuroborreliosis (NB).   
 
1.1.2 B cell development 
 
B cells carry immunoglobulin (Ig) receptors on their surface, are professional antigen-
presenting cells and may evolve to plasma cells upon receiving appropriate 
stimulatory signals. B cells emerge from hematopoietic stem cells in the bone 
marrow. In germ-line DNA, multiple gene segments encode portions of a single Ig 
heavy (H) or light (L) chain. In the case of H chains, variable (V), diversifying (D) and 
joining (J) gene segments are available for the generation of the antigen binding 
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region, while in the case of L chains only V and J regions are encoded in the 
germline. These gene segments cannot be transcribed and translated into H and L 
chains until they are rearranged into functional genes. During B cell maturation, Ig 
gene segments are randomly shuffled by a dynamic genetic system, capable of 
generating more than 1010 combinations (Fig. 1A). A mature immunocompetent B cell 
will contain a single functional H-chain variable (V)-region sequence and a single 
functional L-chain V-region sequence, so that the individual B cell is antigenically 
committed to a specific epitope. The joining of the coding sequences is often 
imprecise and random nucleotides can be added. As a result each B cell carries a 
unique Ig sequence, which is shared only with the successive B cells resulting from 
proliferation. After different selection mechanisms (clonal deletion, receptor editing) 
contributing to B-cell tolerance, surviving naive immature B cells migrate to 
secondary lymphatic organs, where they undergo further maturation processes. The 
mechanisms for eliminating auto-reactive B cells are very stringent; nevertheless, 
some B cells bearing antibodies specific for self-proteins escape the control of the 
immune system.  
B cells that encounter their specific antigen become activated and proliferate. The 
expansion of an antigen-activated B cell leads to a clone of plasma cells and/or 
memory B cells (Fig. 1B). All cells in the expanded clone bear similar Ig gene 
sequences and are therefore specific for the original antigen. Hence clonal expansion 
of a B cell is an unambiguous result of an antigen driven immune response.  
B cell proliferation is accompanied by further differentiation and takes place in 
specialized areas of lymphoid follicles, so called germinal centers. The modifications 
include somatic hypermutation (alteration of the V-regions of Ig genes), affinity 
maturation (selection for B cells with high affinity for the antigen) and isotype-
switching (alteration of the effector function of the expressed antibodies by changing 
the isotype) (Shapiro-Shelef and Calame 2005). B cells in the CNS during 
inflammation typically show somatic hypermutations suggesting that they matured in 
a germinal center and are thus the result of an antigen driven response (Baranzini et 
al. 1999; Baranzini et al. 2002; Owens et al. 1998; Qin et al. 1998; Smith-Jensen et 
al. 2000).  
After germinal center maturation, B cells either develop into memory B cells or 
plasma cells. Plasma cells secrete high levels of antibodies, do not proliferate and 
can be short or long lived. Their ability to survive many years is an important feature 
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of the humoral immune response. They produce antibodies independently of an 
antigen re-stimulation but their survival is particularly dependent upon the 
environment (Manz et al. 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: A. H-chain gene rearrangement and RNA processing events required to generate H chain 
proteins. Two DNA joining are necessary to generate a functional H-chain gene: a DH to JH joining and 
a VH to DHJH joining. B. Maturation and clonal selection of B cell lymphocytes. Clonal expansion of an 
antigen-activated B cell (number 2 in this example) leads to a clone of plasma cells and memory B 
cells. Adapted from Kuby Immunology (Richard A.Goldsby, Thomas J.Kindt, and Barbara A.Osborne 
2000). 
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1.1.3 The CNS as a B cell supporting environment 
 
There is more and more evidence that the brain is a place permissive for B cell and 
plasma cell survival and that in CNS inflammation the brain tissue can even act as a 
B cell supporting micro-environment.  
The inflamed CNS provides a number of survival factors for B cells and plasma cells 
like BAFF and CXCL12. BAFF is one of the crucial factors for B cell survival 
(Schneider 2005). It is locally produced by astrocytes and up-regulated in active MS 
lesions (Krumbholz et al. 2005). CXCL12 plays a role as survival factor for plasma 
cells (Shapiro-Shelef and Calame 2005). It is constitutively generated by endothelial 
cells in the CNS and is also up-regulated in MS lesions (Krumbholz et al. 2006). 
Beside BAFF and CXCL12, many more cytokines promoting B cell differentiation and 
survival are abundant in MS lesions (Cannella and Raine 1995).  
B cell migration to the CNS is still poorly understood but recent studies suggest that 
the homeostatic chemokines CXCL12 and CXCL13 play a role in B cell trafficking to 
the inflamed CNS (Krumbholz et al. 2006; Ransohoff, et al. 2003). 
Clonal expansion of B cells has been detected in the cerebrospinal fluid (CSF) of 
patients with monosymptomatic optic neuritis (Haubold et al. 2004), MS (Baranzini et 
al. 1999; Colombo et al. 2000; Qin et al. 1998; Ritchie et al. 2004) and in patients 
with CNS infections like subacute sclerosis panencephalitis (SSPE) (Burgoon et al. 
1999). However, the anatomical site where these B cell expansions occur, remains 
undetermined. Serafini et al. identified intrameningeal follicles in MS patients, thus 
providing evidence for germinal center reactions in inflamed CNS tissue itself (Aloisi 
and Pujol-Borrell 2006; Serafini et al. 2004). The concept of B cell differentiation in 
ectopic follicles in the CNS is further supported by the finding of B cell differentiation 
stages as they occur only in the germinal center of secondary lymphoid follicles, in 
the CSF of patients with MS and other acute inflammatory neurological disorders 
(Corcione et al. 2004). It is probable that organized B cell follicles with germinal 
centers in the inflamed CNS favor the B cell response sustaining clonal expansion of 
plasma cells and intrathecal antibody production. 
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1.1.4 Oligoclonal immunoglobulins in the cerebrospinal fluid  
 
In the CSF of inflamed CNS, Ig can often be visualized as distinct oligoclonal bands 
(OCB) by isoelectric focusing of CSF proteins. The presence of OCB in the CSF but 
absence in matched serum samples is characteristic for an intrathecal synthesis (Fig. 
2). OCB in CSF samples suggest that the B cell population in this compartment is not 
heterogenous but clonally restricted. It is most likely that clonally expanded plasma 
cells (cePCs) in the CSF are the source for the antibodies of OCB.  
OCB can often be detected in the CSF of patients with autoimmune or infectious 
inflammatory CNS diseases. In infectious CNS diseases, the OCB are typically 
directed against the causative agent (reviewed in (Gilden et al. 1996)). In the case of 
NB it has been shown that the OCB in the CSF contain antibodies directed against 
Borrelia burgdorferi (Bb) (Hansen et al. 1990; Martin et al. 1988a). 
In contrast to infectious CNS disease, the antigen specificity and pathogenic role of 
OCB in presumed autoimmune conditions such as MS remains to be defined. The 
intrathecal Ig production with the formation of OCB is a key feature of MS and the 
OCB remain stable for many years (Walsh and Tourtellotte 1986). The finding of a 
persistent OCB pattern supports the hypothesis that the CNS can provide a long-term 
survival niche for plasma cells. Although different factors in the CSF of MS patients 
(elevated Ig levels, OCB, anti-myelin antibodies) suggest that antibodies play an 
important role in MS, their relevance and impact on MS pathogenesis still remain 
elusive (Martin and Monson 2007). The antigen specificity of the OCB in MS is one of 
the most outstanding questions concerning their pathological relevance and could 
possibly clarify underlying disease mechanisms of MS.  
 
 
 
 
 
 
 
 
Figure 2: Isoelectric focussing gel of CSF and serum proteins (silver stain). Arrow points to one of the 
OCB present in the CSF but not in the serum of the same patient. 
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1.2 Neuroborreliosis 
1.2.1 Introduction 
 
Lyme borreliosis or Lyme disease is a term to describe the various disease states of 
infection with tick- or insect-borne borrelia bacteria. The pattern of clinical 
manifestations of Lyme borreliosis spread over four organ systems, the skin, the 
nervous system, the joints, and the heart.  
 
1.2.2 History 
 
Lyme borreliosis was first described in 1975 in the town of Lyme (Connecticut, USA) 
and has now become a widespread infectious disease in the USA and Eurasia. While 
a connection of the disease with ticks has long been assumed, only in 1982 was a 
novel spirochete first isolated from ticks and subsequently from patients with Lyme 
disease (Burgdorfer et al. 1982; Benach et al. 1983). The spirochete was named 
Borrelia burgdorferi in honor of its discoverer Willy Burgdorfer, an expert in tick-borne 
diseases at Rocky Mountain Labs in Hamilton, Montana. 
 
1.2.3 Epidemiology 
 
Lyme borreliosis occurs mainly in the northern hemisphere from North America to 
Europe and throughout Asia. The underlying infectious agent Bb is usually 
transmitted by the bite of certain ticks of the species Ixodes.  The tick has a two year 
three-stage life cycle (larval, nymphal, adult) and feeds once during each stage (Lane 
et al. 1991). The tick may become infected at any stage of its life cycle by feeding on 
a host that is a natural reservoir for Bb. The main hosts of borrelia are mice, dormice, 
deer, voles as well as lizards (Hengge et al. 2003). In Europe, the chance of 
becoming ill due to Bb after a tick bite is probably below 1% (Paul, et al. 1987). 
Several factors play a role in the transmission of Bb from ticks to human beings. On 
the one hand, the proportion of infected ticks in a certain geographic area is relevant. 
On the other hand, the risk of transmission of Bb from an infected Ixodes tick is 
related to the duration of feeding.   
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1.2.4 Causative agent: Borrelia burgdorferi 
 
The spirochaetal bacteria causing Lyme borreliosis belong to the genus Borrelia and 
further to the species of Borrelia burgdorferi sensu lato. The most prominent disease 
causing genospecies are Borrelia burgdorferi sensu stricto, Borrelia afzelii and 
Borrelia garinii. The ultrastructure of Borrelia species resembles other spirochetes 
characterized by an axial filament composed of flagella, which runs lengthways 
between the cell wall and outer membrane. This allows the spirochete to move in a 
corkscrew fashion (Barbour and Hayes 1986). Bb is a Gram-negative organism that 
is 10-30 um long. It can be cultured in liquid cultures in Barbour-Stoenner-Kelly (BSK) 
II medium and has under optimal conditions (30-34°C, microaerophilic milieu) a 
generation time of 7 to 20 hours. Important antigens of Bb are the 41 kD flagellin 
protein, several outer surface proteins (Osp A-F) and a 60 kD antigen, which has 
been termed "common antigen" and belongs to the heat shock protein family. The 
genome of Bb (strain B31) has been sequenced (Fraser et al. 1997). It includes a 
linear chromosome as well as 9 linear and 12 circular plasmids - by far the largest 
number of plasmids found in any known bacterium (Casjens et al. 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Borrelia Taxonomy 
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1.2.5 Clinical manifestation 
 
Lyme borreliosis has many signs and symptoms and the clinical manifestations 
spread over four organ systems, the skin, the heart, the joints and the nervous 
system. The incubation period from infection to the onset of symptoms is usually 1-2 
weeks, but can be much shorter or even as long as one month. The course of the 
disease can be divided into an acute or early (the first weeks or month) and a chronic 
or late phase (after several month or years) (Pfister et al. 1994). 
Skin: The most common manifestation of early Lyme borreliosis is erythema migrans, 
which is a rash that spreads out centrifugally, generally at the site of a tick bite 3 to 
30 days after the bite. It is sometimes homogeneous but usually it is ring-shaped 
(Louis Reik 1991). 
Heart: Cardiac complications of Lyme borreliosis may occur in up to 8% of patients. 
The most common feature of Lyme carditis is a transient atrioventricular block of 
various degrees (Nagi et al. 1996). 
Joints: About 60% of untreated patients with erythema migrans in the USA develop 
arthritis (Steere et al. 1987). The brief attacks of arthritis occur weeks to months after 
the initial infection and some patient develop persistent joint inflammation.  
Nervous system: Neurological features of lyme borreliosis or NB include the 
Bannwarth syndrome (meningoradiculoneuritis), meningitis and cranial nerve palsies. 
The Bannwarth syndrome represents the second most common clinical manifestation 
of acute borrelia infection in Europe after erythema migrans and is characterized by 
CSF lymphocyte pleocytosis and intense radicular pain (Kaiser 1998). Frequently, 
these patients have also sensitive irritations and an occasional paresis is 
characteristically asymmetrically. In three-quarters of patients with Bannwarth 
syndrome further neurological symptoms occur after 1-4 weeks. 
Cranial nerve palsies have been described for different cranial nerves but by far the 
most common is an involvement of the facial nerve. Unilateral and bilateral facial 
paralysis may occur in up to 11% of patients with Lyme disease (Clark et al. 1985). 
Occasionally, a chronic encephalomyelitis develops with marked intrathecal 
production of antibodies against the spirochete (Oschmann et al. 1998). Magnetic-
resonance imaging usually shows diffuse white matter lesions (Fig. 4). Main 
differences to MS are the presence of borrelia specific antibodies in the CSF and 
usually a higher cell count and more pronounced impairment of the blood-CSF 
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barrier. It is still unknown, if the chronic neurological involvements in NB are due to 
persistent Bb infection or the result of an aggressive autoimmune response. Further 
research is necessary to clarify the underlying mechanisms. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Magnetic resonance imaging scans of the brain of a 49-year-old man with chronic 
progressive Lyme encephalomyelitis. The patient had tetraspastic syndrome and ataxia of 1 1/2 years’ 
duration. CSF showed lymphocyte pleocytosis and intrathecal Bb antibody production. Arrows indicate 
periventricular lesions of the white matter. Adapted from Pfister et al. 1994 (Pfister et al.1994) 
 
1.2.6 Diagnosis 
 
The diagnosis of Lyme borreliosis is based on clinical symptoms and laboratory data. 
In locations where Lyme borreliosis is endemic, the clinical diagnosis of erythema 
migrans, which does not occur in all cases, is sufficient. Culturing Bb from specimens 
(from erythema migrans, plasma samples, CSF) allows a definitive diagnosis but is 
very difficult. Likewise a PCR for detecting Bb DNA can be made. But most important 
are serological test measuring the body's immune system response, including 
enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence assay 
and western blot. 
For diagnosing NB, both serum and CSF have to be tested and the diagnosis is 
supported by the demonstration of an intrathecal synthesis of borrelia-specific 
antibodies in the CSF. Depending on the constellation of clinical and laboratory data, 
the diagnosis of NB is possible, likely or certain (Kaiser 1998).  
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1.2.7 Treatment 
 
Traditionally lyme borreliosis is treated with a course of antibiotics. Most treated 
patients have an excellent prognosis, though some patients with NB may suffer from 
residual deficits and/or progression of the disease (Logigian et al. 1990).  
 
1.2.8 Immune response and autoimmunity 
 
The innate and the acquired immune response play both an important role in the 
recognition and elimination of foreign microorganisms. While innate immunity 
depends on a number of barriers that are effective against a wide variety of 
pathogens, adaptive immunity is specific for particular microorganisms or foreign 
molecules.  
A key component of the innate immune response is the complement system. It is 
composed of a collection of serum proteins and cell surface receptors that are part of 
the initial immune response to infection by bacteria, fungi, viruses or parasites. There 
are three pathways of complement activation. Two of them - the alternative and the 
mannan-binding lectin pathway - are initiated by the interaction of complement 
components with the surface of microorganisms. The third pathway - the classical 
activation pathway - requires the formation of antigen-antibody complexes on the 
surface of the microorganism. The three main consequences of complement 
activation are opsonization of pathogens, the recruitment of inflammatory cells and 
direct killing of pathogens.  
Bb can activate the classical and alternative pathway of the complement cascade in 
normal human serum, but is resistant to complement-mediated lysis (Kochi et al. 
1991). This resistance results from the binding of the complement inhibitor factor H to 
proteins expressed on the surface of Bb and the subsequent inactivation of 
complement component C3b (Alitalo et al. 2001; Alitalo et al. 2002; Kraiczy et al. 
2003). 
Bb can be ingested and killed by different human phagocytic cells. The phagocytosis 
of the spirochetes can be both independent of opsonization with antibody and 
mediated by the Fc receptor (Montgomery et al. 1994; Peterson et al. 1984). 
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The acquired immune response encompasses the generation of clonally selected 
effector and memory T and B cells.  
In patients with NB, activated T cells are recruited into the CSF compartment during 
acute infection of the nervous system (Jacobsen et al. 2003; Rupprecht et al. 2005a; 
Rupprecht et al. 2005b). Studies with CSF derived T cells demonstrated clones 
reactive for Bb derived antigens but also other clones specific for CNS self-antigens 
(Martin et al. 1988b). Further studies found Bb specific T cells cross-reacting with 
self-antigens suggesting molecular mimicry to be responsible for autoimmune 
mechanisms leading to chronic disease manifestation (Lunemann et al. 2006; 
Hemmer et al. 1999). 
In NB, the immune response is highly focused to the CNS, involving pleocytosis, 
disruption of the blood-brain barrier and intrathecal antibody synthesis (Pfister et al. 
1994; Wilske et al. 1986). 
Various lymphomononuclear cells accumulate in the CSF of patients with NB, most 
typically plasma cells (Cepok et al. 2003; Sindern and Malin 1995).  
Furthermore, high levels of IL-6, IL-8 and IL-10 are found in the CSF (Cepok et al. 
2003). These interleukines promote the development of a humoral immune response: 
IL-10 stimulates B-cell proliferation and differentiation and induces the secretion of 
Igs (Moore et al. 2001). IL-6 induces the final maturation of B cells into Ig secreting 
plasma cells, favoring the secretion of the IgG1 subtype in particular (Taga and 
Kishimoto 1992). IL-8 is a chemotactic factor for various immune cells (Kimata et al. 
1992). The combined effect of these cytokines may lead to pleocytosis and supports 
differentiation of B cells.  
In NB, the levels of distinct Ig clones in the CSF are elevated and can be 
demonstrated as OCB by isoelectric focussing (Kruger et al. 1981). The finding of 
OCB and an elevated Ig index in the CSF point to a local production of the Ig in the 
CSF compartment. Analysis of Ig in the CSF has revealed specificity for Bb (Hansen, 
et al. 1990; Martin et al. 1988a) but also for CNS auto-antigens (Kaiser 1995). 
Bb specific antibodies can persist for 10-20 years (Kalish et al. 2001) and Ig in sera 
of patients with lyme disease and of mice infected with Bb, have been demonstrated 
to protect against infection with Bb by passive immunization (Barthold and 
Bockenstedt 1993; Fikrig et al. 1994).  
Different neural auto-antibodies that cross-react with Bb have been described. Sigal 
and colleagues identified an antibody specific for Bb flagellin that cross-reacts with 
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the heat shock protein 60 and binds to human peripheral nerve (Dai et al. 1993). The 
same antibody was also found to bind neuroblastoma cell lines and to slow down 
neurite outgrowth in culture (Sigal and Williams 1997). Another study described 
antibodies specific for Bb OspA proteins that cross-react with neurons in human 
neural tissue (Alaedini and Latov 2005). These studies support the hypothesis that 
autoimmunity due to molecular mimicry may play a role in NB. Such mechanisms are 
also known to be important in Lyme arthritis where human LFA-1 can serve as a 
cross-reactive auto-antigen for Bb OspA-reactive Th1 cells, resulting in treatment 
resistant Lyme arthritis (Gross et al. 1998).  
However, the underlying mechanisms leading to chronic NB are unknown. The role of 
autoimmunity either triggered by molecular mimicry or by other mechanisms has to 
be further studied. 
 
1.2.9 Vaccines 
 
Lyme disease vaccine development has targeted the OspA protein of Bb. Two 
commercial recombinant OspA vaccines were formulated and have been shown to 
be effective (Connolly and Benach 2005). However, these vaccines have now been 
withdrawn from the commercial market due to limited confidence in these products as 
a result of indications for cross-reactivity of OspA with self-antigens (Gross et al. 
1998).  
 
Introduction  13 
1.3 Multiple Sclerosis 
1.3.1 Introduction 
 
MS is one of the most common neurological diseases of young adults in Europe and 
North America (Noseworthy et al. 2000). MS patients characteristically display 
chronic multifocal sclerotic plaques in the CNS from which the disease gets its name. 
MS is thought to be caused by the interaction of multiple genetic and environmental 
factors, yet the initial causative trigger is still unknown.  
 
1.3.2 Epidemiology 
 
The prevalence of MS varies considerably around the world. The prevalence rate is 
highest in northern Europe, southern Australia and the middle part of North America 
(Noseworthy et al. 2000). The reasons for the variation in the prevalence of MS 
worldwide are not understood. However it is hypothesized that both environmental 
factors and population-specific genetics probably play a role.  
Twin studies demonstrated increased concordance rates among monocygotic (25-
30%) compared to dizygotic (2-5%) twins with MS (Kenealy et al. 2003). These data 
provide clear evidence for a genetic component in the disease susceptibility; however 
the concordance rate in monozygotic twins of significantly less than 100% also 
highlights the important contribution of environmental factors.  
 
1.3.3 Clinical manifestation 
 
MS typically begins in early adulthood and has a variable prognosis. The clinical 
manifestations are diverse, since every part of the CNS can be affected. Common 
presenting features include weakness, paraesthesia or focal sensory loss, optic 
neuritis, diplopia, ataxia and vertigo. Other manifestations can include painful muscle 
spasms, trigeminal neuralgia, fatigue and depression, subtle cognitive difficulties, 
psychiatric disturbances and seizures (Love 2006). Characteristic for MS are CNS 
white matter lesions and OCB of Ig detected by magnetic resonance imaging and 
elecrophoresis of cerebrospinal fluid, respectively. The MS disease course can be 
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either relapsing and remitting or it can be progressive. The latent phase between the 
first manifestation of MS and the first relapse can be many years and the intervals 
between relapses are variable. For the clinical diagnosis the revised criteria of 
McDonald et al. are most widely used (Polman et al. 2005).  
 
1.3.4 Pathogenesis 
 
The pathological hallmarks of MS are demyelinated plaques within the white matter 
combined with inflammatory infiltrates consisting of lymphocytes and activated 
macrophages. The demyelination is associated with oligodendrocyte loss. Gliosis 
with astrocyte proliferation and glial fibre production are also important pathological 
features of MS.  
There is increasing evidence that neuroaxonal damage is a key feature in MS lesions 
and that it has a major impact on permanent neurologic deficits (Trapp et al. 1999) . It 
may occur either in parallel with myelin destruction or during a second phase, when 
the axon is demyelinated and more susceptible to damage.  
There is a variable degree of remyelination in the plaques (Noseworthy et al. 2000) 
and  oligodendrocyte precursor cells can be found (Wolswijk 1998). However, the 
mechanisms that promote endogenous remyelination are still poorly understood.  
Pathological similarities between MS and the animal model of experimental allergic 
encephalomyelitis and the detection of auto-reactive T and B cells in MS patients 
provide evidence that MS could be an autoimmune disease. 
Activated auto-reactive T cells are thought to enter the blood brain barrier, and 
different factors like up-regulated adhesions molecules on the endothelial cells or 
activated proteases can facilitate their entry into the CNS. The T cells can then get 
stimulated further or become anergic by the recognition of their target antigen on 
antigen-presenting cells. Moreover they can stimulate B cells to produce auto-
aggressive (or repair enhancing) antibodies. A cascade of events, which includes the 
production of different cytokines, can then result in the immune mediated injury to 
myelin and oligodendrocytes (Fig. 5). 
One possible mechanism leading to tissue injury includes the assistance of myelin 
specific antibodies. It has been shown that antibodies against myelin oligodendrocyte 
glycoprotein (MOG) can be found within MS lesions (Genain et al. 1999) and that 
MOG-specific antibodies can cause demyelination (Linington et al. 1988; Piddlesden 
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et al. 1993). A possible scenario is that these antibodies and their underlying B cells 
gain access to the CNS through the disrupted blood brain barrier after initial T cell 
mediated inflammatory responses. 
However, the role of myelin specific antibodies is still debated as such antibodies 
have been detected in the serum and CSF of MS patients, but also in control subjects 
(Karni et al. 1999; Lindert et al. 1999; Mantegazza et al. 2004; Markovic et al. 2003; 
Reindl et al. 1999; Sun et al. 1991; Xiao et al. 1991).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Possible Mechanisms of Injury and Repair in Multiple Sclerosis.  
Genetic and environmental factors may contribute to the survival, activation and invasion of auto-
reactive T cells and demyelinating antibodies into the central nervous system. Local factors and 
antigen dependent mechanisms play important roles in the immune responses leading to the injury 
and possible repair of myelin membranes. Adapted Noseworthy et al. (Noseworthy et al. 2000). 
Introduction  16 
1.4 Goal of this work  
 
A common characteristic of chronic inflammatory diseases of the CNS is the 
presence of oligoclonal Ig in the CSF, a feature suggesting the presence of a specific 
humoral antigen driven immune response in the CNS compartment. While it is known 
that in chronic CNS infections some of the OCB are directed against the causative 
infectious agent, the specificity and disease relevance of OCB in other chronic 
inflammatory diseases of the CNS such as MS remain unknown. So far the analysis 
of the antigen specificity and disease relevance of antibody responses in the CSF 
has been hampered by both the limited availability and oligo/polyclonal composition 
of CSF Ig.  
The aim of this study was to dissect intrathecal antibody responses down to the 
single plasma cell level. By accurate sequence analysis we could identify plasma 
cells, which were - as a result of an antigen driven immune response - clonally 
expanded. Subsequent recombinant reconstruction of the antibodies originally 
produced by these cePC permitted their proper investigation.  
Investigations with NB CSF were aimed on the one hand at evaluating our 
experimental set-up and on the other hand at investigating characteristics of the 
complex humoral immune response in NB. The production of antibodies from cePC 
of MS patients CSF was aimed at unraveling their antigen or tissue specificity. 
Such knowledge could provide fundamental insights into the immunopathological role 
of antigen driven humoral immune responses in CNS inflammation.  
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2 RESULTS 
 
2.1 Strategy for the production of recombinant antibodies from 
CSF derived clonally expanded plasma cells   
 
2.1.1 Single cell RT-PCR 
 
Our goal was to establish a system that allows the recombinant resurrection of 
antibodies originally produced by cePC. As a correct pairing of H and L chain Ig 
products is crucial for an antibody‘s specificity we had to obtain sequence information 
for both chains from each individual cell. The only way to achieve that is to amplify 
matching H and L chain Ig genes from the mRNA of a single cell. Figure 6 shows a 
schematic diagram of the method to produce recombinant antibodies originally 
secreted by single plasma cells. There are different families of Ig V region genes that 
can be used by a B cell, therefore we used for the amplification a mix of primers 
containing one for each of the different families. As the amount of mRNA of a single 
cell is very small, a highly sensitive system had to be established.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Schematic diagram of the method applied to produce recombinant antibodies with the same 
antigen specificity and affinity as the antibodies originally secreted by single plasma cells.  
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To establish single cell RT-PCR for the Ig genes from individual FACS sorted plasma 
cells, different protocols were initially tested.  Different conditions and ingredients for 
the RT-PCR reaction as well as different primer sets were tested.  
Single plasma cells were sorted directly into RT-buffer, immediately frozen on dry ice 
and stored at -80 °C until further use.  For the amplification of the Ig V region genes a 
reaction mix composed of RT-buffer, dNTP, enzyme-mix, RNAse out and dH20 was 
added to the plasma cell on ice. The cell was lysed by gently pipetting up and down 
and the mix was then split into three reactions containing gene-specific primers for 
either the H, the κ or the λ Ig chain. After reverse transcription reaction a first PCR 
amplification round was performed using PCR primers, specific for the Ig H, κ and λ 
Ig chain genes. The reverse primers, specific for the C regions of H, κ and λ Ig genes 
were used as described (Owens et al. 2003). As forward primers, a mix of primers 
specific for the conserved framework regions 1 of the different V region families of the 
Ig genes was used, which was adapted from Andris-Widhopf et al. (Andris-Widhopf et 
al. 2001).  
Ig sequences were analyzed and assembled into groups of identical Ig H chain V 
region genes using SeqMan software (DNASTAR). If a variable region with a specific 
CDR3 region was amplified from more than one plasma cell, it was defined to be the 
product of a cePC. As a number of precautions had been taken to avoid cross-
contamination between wells of PCR plates (see Materials and Methods), and we 
also obtained several "unique" sequences from single plasma cells analyzed in the 
same PCR experiment, we expected that sequences with 100% homology were not 
the product of contamination. 
To obtain further information about potential maturations of the antibodies from cePC 
we analyzed their sequences for germline segment usage and their germline 
homology via the V-Quest tool on the IMGT website (Giudicelli et al. 2004).  As 
further described in the results section, we found significant variations in the 
expressed segments compared to the germline segments indicating that processes 
of affinity maturation had occurred.  
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2.1.2 Cloning and recombinant expression of immunoglobulin amplicons 
 
For the recombinant expression of the cePC derived Ig genes, we used the system 
described by Wardemann et al. (Wardemann et al. 2003), which allows the 
generation of recombinant human monoclonal antibodies (mAb) with a human IgG1 
backbone using a eukaryotic expression system. 
Therefore the PCR H and L chain Ig amplicons from cePCs were reamplified in a 
nested second round PCR with primers containing restriction sites (Wardemann et al. 
2003). After digesting, these products were cloned into vectors containing the Ig H, κ 
or λ C regions (Vectors were kindly provided by H. Wardemann, Max-Planck Institut 
für Infektionsbiologie, Berlin, Germany).  
To produce the recombinant antibodies we transiently transfected 293T human 
embryonic kidney cells with both plasmids coding for the H and L chain Ig of the 
desired antibody. Eight days after transfection and culture in serum free medium, we 
purified the antibodies from the supernatant using proteinG column on Fast Liquid 
Protein Chromatography. Figure 7 shows a SDS-gel of purified antibodies stained 
with silver to demonstrate their purity. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: High purity of generated human recombinant monoclonal antibodies. 12% acrylamide gel 
run under reducing conditions and stained with silver. 100ng of antibodies were loaded after FPLC 
purification.  
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2.1.3 Proof of principle: recombinant expression maintains specificity 
and affinity 
 
In pilot experiments we evaluated the fidelity of the recombinant expression system 
described. We therefore amplified the V regions of the Ig genes of the well known 
MOG specific hybridoma antibody 8-18c5 and cloned them into the previously 
described expression vectors. We thereby produced a chimeric antibody (hu8-18c5) 
of the variable region of the originally murine 8-18c5 (m8-18c5) with a human IgG1 
backbone. Using MOG coated ELISA we compared the avidity of both m8-18c5 and 
hu8-18c5 and could show that it is not changed by the process of recombinant 
expression (Fig. 8). These results confirm that we can faithfully conserve the 
specificity and affinity of the originally produced antibodies when producing them in 
the described recombinant system.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: The avidity of m8-18c5 is maintained after cloning and recombinant expression as human 
chimeric hu8-18c5. Shown are the results of competition ELISAs of biotinylated vs. non-biotinylated 
m8-18c5 (?, Ki=10-9) and biotinylated vs. non-biotinylated hu8-18c5 (?, Ki=10-9) for their binding to 
recombinant MOG. 
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2.2 Production and characterization of recombinant antibodies 
from clonally expanded CSF plasma cells from a 
neuroborreliosis patient 
 
As described in the introduction, a common characteristic of NB CSF is the presence 
of oligoclonal Ig, a feature suggesting the existence of a CSF specific antigen driven 
immune response. So far, the analysis of Ig in the CSF has revealed specificity for Bb 
(Hansen et al. 1990; Martin et al. 1988a) but also for CNS auto-antigens (Kaiser 
1995). However, mechanisms underlying Bb directed humoral immune defense and 
CNS tissue damage still remain poorly understood and a more in-depth 
characterization of the focused antibody response in the CSF has been hampered by 
both the limited availability and oligo/polyclonal composition of CSF Ig.  
To gain further information on the immunological properties of antigen driven immune 
responses in the CSF of patients with NB, we recombinantly reconstructed antibodies 
derived from cePCs of NB CSF. 
Furthermore, as it is known that in NB part of the OCB are specific for Bb, we 
expected that some of the recombinant antibodies derived from cePcs - the putative 
source of the OCB antibodies - would be specific for Bb. We thereby wanted to verify 
that we are indeed able to produce the disease relevant antibodies with the applied 
method. With respect to the unraveling of the specificity of plasma cells from MS CSF 
with this method, this proof of principle is of major importance.  
 
2.2.1 RT-PCR analysis of individual FACS sorted plasma cells from NB 
CSF demonstrates clonal expansion  
 
Eighty-eight CD138+ plasma cells were sorted from the CSF of a patient with NB into 
wells of a 96 well PCR-plate at a ratio of 1 cell/well. Single cell RT-PCR of Ig genes 
yielded Ig H chain amplicons and corresponding sequence information from 54 out of 
the 88 (61.4%) individual plasma cells. By assembling the Ig H chain V region genes 
in groups of sequences sharing identical heavy chain CDR3 regions, we were able to 
discern 3 independent cePC (RA17, RA20 and RA77; Tab. 1). Matching Ig L chain 
gene amplicons were obtained for each of the 3 cePC.  
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In the V region sequences of RA17, RA20 and RA77 we found several mutations of 
the germline segments, which is a sign that affinity maturation processes took place 
for these antibodies (Tab.1).  
Table 1 summarizes the frequencies of the expanded plasma cells and the 
characteristics of the corresponding V-H and V-L sequences.  
 
 
 
 
 
 
 
 
Closest Germline  
Clone Frequency  V segment % Homology J segment D segment CDR3 
        
RA77 4/54 H chain: IGHV5-a 97.6 IGHJ5 IGHD2-15 AGEAAGTRIDRWFDP 
  L chain: IGLV9-49  IGLJ3  GADHGSGSNFVWV 
RA20 3/54 H chain: IGHV4-59 98.2 IGHJ6 IGHD5-24 ARVPGERDGYHYMAYAMDV
  L chain: IGLV3-1  IGLJ3  QAWDSSTLGV 
RA17 4/54 H chain: IGHV5-a 97.8 IGHJ32 IGHD6-6 ASLAARGAFDI 
  L chain: IGLV3-25  IGLJ3  QSADSSGSYRV 
 
Table 1: Characteristics of VH and VL region sequences of recombinant antibodies derived from 
expanded CD138+ CSF plasma cells from NB patient RA. Frequency indicates the number of the 
respective H chain sequences containing the indicated H chain CDR3 region among all plasma cells 
analyzed by PCR. Shown are the most homologous V, D and J germline segments, degree of 
homology to the closest germline segment for the H chain V region and the respective CDR3 amino 
acid sequence. 
 
2.2.2 Recombinant antibody RA77 is specific for Borrelia flagellum 
protein p41 
 
Correctly paired Ig H and L chain amplicons of each of the three cePC were cloned 
into the previously described eukaryotic expression vectors and expressed as 
recombinant human mAbs (RA77, RA20, RA17). In ELISA experiments RA77 
showed clear reactivity with extracts of 4 different strains of Borrelia (B. burgdorferi 
sensu strictu, B. afzelii, B. garinii, B. valaisiana) while no binding to E.coli could be 
detected. No significant binding to any Borrelia strain could be detected for RA17 and 
RA20 (Fig. 9A). To further investigate Borrelia specificity of RA77 and rule out 
possible cross-reactivity with other spirochetes we performed immunofluorescence 
experiments with Bb and Tp attached to microscopy slides. While specific binding of 
RA77 to Bb could be confirmed, no binding to Tp could be detected (Fig. 9B-G).  
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In immunoprecipitation experiments using RA77 together with Bb lysate, a protein 
band of approximately 40 kDa was detectable in the precipitate. In the control 
immunoprecipitation with hIgG1 no bands in addition to the expected Ig H and L 
chain bands were detected (Fig. 10A). MALDI-TOF analysis of the 40 kDa band 
revealed peptide masses matching theoretically derived masses from tryptic-digested 
flagellin protein p41 of Bb. ELISA experiments with purified recombinant p41 
flagellum protein confirmed the result from mass spectrometry (Fig. 10B). 
Competition experiments using RA77 and native Bb lysate demonstrated a high 
affinity interaction (Ki=1x10-9). Interestingly, the interaction between RA77 and 
recombinant p41 yielded a 1000-fold lower affinity (Ki=1x10-6) (Fig. 10C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Specificity of RA77 for Bb without cross-reactivity to E.coli and Tp. A. ELISA coated with 
5ug/ml of either Borrelia lysate of different Borrelia strains or E.coli lysate. Tested recombinant mAbs 
RA17, RA20, RA77 were used at a concentration of 10ug/ml. Staining of Bb attached to polycarbonate 
slide with: B. RA77 C. anti-p41 antibody 1C11 D. Overlay of B and C. Staining of Tp attached to 
polycarbonate slide with: E. RA77 F. anti-TP serum. G. Overlay of E and F.   
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Figure 10: Bb-specific mAb RA77 recognizes p41 flagellin protein. A. Immunoprecipitation of p41 
flagellin protein from Bb lysate by RA77. The ~40kDa band corresponds to the p41 flagellin protein 
(framed), as verified by MALDI TOF analysis. No such band was detected in immunoprecipitation with 
hIgG1. The protein bands around 50 kDa and 25 kDa correspond to the Ig H and L chain of the RA77 
and hIgG1 control antibody. Molecular mass standards are indicated on the left. B. Verification of the 
specificity of RA77 for p41. Shown are the results of an ELISA experiment with RA77 binding to 
recombinant p41 and BSA (neg. control). C. Different binding affinity of RA77 to native Bb lysate and 
recombinant p41. Shown are the result of competition ELISAs of biotinylated vs. non-biotinylated 
RA77 for their binding to Bb lysate (?, Ki=10-9) and recombinant p41 (?, Ki=10-6). 
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2.2.3 Recombinant antibody RA17 is specific for auto-antigens in CNS 
myelin 
 
Immunofluorescence stainings of cryostat sections of frozen human facial nerve 
tissue showed reactivity of RA17 with the myelin component of the nerve, as 
identified by co-stainings with the myelin specific antibody 8-18c5 (Fig. 11F-G). 
Furthermore immunofluorescence stainings on human white matter tissue revealed a 
specificity of RA17 for structures stained with the myelin antibody 8-18c5 (Fig. 11A, 
D). The structures stained by RA17 enfold neurons, as demonstrated by double 
immunofluorescence staining with a neurofilament specific antibody, thus indirectly 
confirming the myelin reactivity of RA17 (Fig. 11E). In contrast Borrelia specific RA77 
antibody, antibody RA20 and human IgG1 isotype control didn't show any reactivity 
with human CNS tissue (Fig. 11B-C). None of the antibodies examined (RA17, RA20, 
RA77) stained (Fig. 11H-K), kidney and lung tissue controls (not shown). 
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Figure 11:  CNS reactivity of RA17. Micrographs of immunofluorescence stainings of human white 
matter (A-E), facial nerve (F-G) and colon tissue (H-K). White matter stainings performed with myelin-
specific antibody 8-18c5 (A-D) and RA17 (A), RA20 (B), RA77 (C). D. shows a greater magnification 
of A. E. shows staining of white matter tissue with neurofilament-specific antibody and RA17. Stainings 
of human facial nerve tissue with F. myelin-specific antibody 8-18c5 and RA17. G. shows a greater 
magnification of F. Stainings of human colon tissue with H. RA17. J. RA20. K. RA77. Nuclei are 
stained with Hoechst 55432 (blue).   
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2.3 Characterization of recombinant antibodies derived from 
clonally expanded CSF plasma cells from MS patients 
 
There is strong evidence that B cells and antibodies play an important role in the 
immune pathogenesis of MS (Link 1978). OCB are a hallmark of MS CSF 
(Tourtellotte et al. 1980) indicating the presence of an antigen driven B cell response 
in the CSF.  However, little is known about the immunopathological role of the cePC 
and the target antigens of their antibodies remain to be determined.   
We therefore produced recombinant human mAb from CSF derived cePC from four 
patients with early or definite MS. Table 2 shows the frequencies of the expanded 
plasma cells and the characteristics of the corresponding V-H and V-L sequences.  
Using immunofluorescence stainings of human MS lesion tissue, my colleague 
Melanie Harrer could show, that seven of these antibodies (RRMS1-36, CIS1-40, 
CIS1-86, CIS1-92, RRMS2-34, RRMS2-101, SPMS1-61) specifically recognize 
myelin while the remaining two antibodies (RRMS1-6, RRMS2-106) displayed 
astroglial reactivity.  
Closest Germline   
Clone Frequency   
V  
segment 
% 
Homology 
J 
segment
D 
segment CDR3 
        
CIS1- 
40 2/21 H chain: IGHV4-31 93.6 IGHJ5 IGHD3-22 ARNPVTDYSTGYLAWGPKNDRAWERKWFDS 
  L chain: IGKV1-12  IGKJ2  QQANNFPYT 
CIS1- 
86 5/21 H chain: IGHV4-b 93 IGHJ4 IGHD2-8 ARGAVFQARGTAFDL 
  L chain: IGKV1-5  IGKJ2  QQYNSYSNT 
CIS1- 
92 2/21 H chain: IGHV3-7 96.9 IGHJ3 IGHD6-19 ATYPNRITVAGFDAFEI 
  L chain: IGKV1-9  IGKJ4  QQLHSYPLT 
RRMS1- 
6 13/57 H chain: IGHV4-4 87.3 IGHJ6 IGHD1-26 ARGLSGSPVLRRNPLPGGYYYGMDV 
  L chain: IGKV1-39  IGKJ4  QQSYSSPLT 
RRMS1-
36 4/57 H chain: IGHV3-7 92.5 IGHJ6 IGHD1-1 ARDRFWHVQLELDHPSGMAV 
  L chain: IGKV1D-17  IGKJ1  LQHKIYPPT 
RRMS2-
34 2/66 H chain: IGHV3-33 94.4 IGHJ3 IGHD2-15 ARDKTVGYCSAGSCYGTTDALDI 
  L chain: IGKV1-5  IGKJ1  QQYDTYPWT 
RRMS2-
101 4/66 H chain: IGHV1-18 92.4 IGHJ6 IGHD3-10 ARGVAANYYYYGMDVW 
  L chain: IGKV1D-33  IGKJ1  QRYDDLPTWS 
RRMS2-
106 4/66 H chain: IGHV3-21 91.9 IGHJ6 IGHD3-16 ARDRVPFELRFYGMDV 
  L chain: IGKV3D-15  IGKJ2  QQYSHWGHT 
SPMS1- 
61 4/24 H chain: IGHV1-69 93.1 IGHJ6 IGHD2-15 ATCTSCTGGSCYHKCNYYHGMDV 
    L chain: IGKV1-47   IGKJ3   ATWDDNLSGPV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Characteristics of VH and VL region sequences of recombinant antibodies derived from 
expanded CD138+ CSF plasma cells from MS patients. Frequency indicates the number of the 
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respective H chain sequences containing the indicated H chain CDR3 region among all plasma cells 
analyzed by PCR. Shown are the most homologous V, D and J germline segments, degree of 
homology to the closest germline segment for the H chain V region and the respective CDR3 amino 
acid sequence. 
2.3.1 Human brain cDNA expression library  
 
To investigate the cognate antigens of the recombinant MS-mAb, we applied a novel 
protein array, which has already been used to delineate antigen specificities of CSF 
Ig derived from MS patients (Cepok et al. 2005). We conducted these array 
experiments prior to the immunofluorescence staining experiments mentioned above. 
The protein array was generated from a human fetal brain cDNA expression library 
comprising 37’000 bacterial expression clones. We conducted several of these array 
experiments with either individual MS-mAb or mixes of MS-mAb. Immunoreactivity 
was visualized using an HRP-conjugated anti-human IgG. Between 10 and 74 
expression clones with a specific staining above background were identified on 
arrays incubated with individual MS-mAbs (mAb-RRMS1-6: 74, mAb-CIS1-40: 10, 
mAb-RRMS2-106: 21). Figure 12 shows an example of antibody binding to a 
expression clone spotted in duplicate on the array.  A total of 66 of these arrayed 
expression clones were ordered, subsequently their cDNA inserts were sequenced 
and the corresponding AA sequences were determined. From several other clones, 
sequence information was obtained from the RZPD (German Resource Center for 
Genom Research), the supplier of the protein-arrays used.  
In several of these positively stained clones the transgene was expressed in a wrong 
reading frame generating artificial protein sequences.  
All the ordered clones, irrespective of whether they were expressed in the correct 
frame or not, were purified and ELISA experiments were conducted. Unexpectedly, 
no clear specificity for any of the MS-mAb could be detected in these ELISA 
experiments. However, some MS-mAbs interacted with certain proteins, but only at a 
high concentration of 10ug/ml but not with 3ug/ml. Nevertheless, low affinity 
interactions cannot be excluded. Table 3 summarizes the possible antigens 
delineated from the protein-arrays and subsequent ELISA experiments.  
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Figure 12: Part of the makroarray comprising bacterial expression clones probed with MS-mAb. 
Positive binding is visualized with anti human IgG-HRP and fluorescence substrate. Example for 
positive binding to clones spotted in duplicate is framed in red.  
 
 mAb RZPD 
Clone 
Clone ID Protein-Blast
    
    
mAb-RRMS1-6 1 H08523 Vimentin 
 4 F02536 out of frame 
 9 O24552 Vimentin 
 23 H06528 out of frame 
 39 H20557 Sequestosome 1 (SQSTM1) 
    
mAb-CIS1-40 4 F02536 out of frame 
 22 E09526 Debrin like protein (DBNL) 
 58 C18590 Ufm 1-conjugating enzyme 1 (UFC1) 
 63 F16598 Lipidosin, MP-binding enzyme (ACSBG1) 
    
mAb-CIS1-86 4 F02536 out of frame 
 22 E09526 Debrin like protein (DBNL) 
 63 F16598 Lipidosin, MP-binding enzyme (ACSBG1) 
    
mAb-RRMS2-106 4 F02536 out of frame 
 9 O24552 Vimentin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Possible interaction partners delineated from protein macroarrays and subsequent ELISA 
experiments. 
 
Results  30 
2.3.2 Antibodies produced by cePC from MS CSF do not react with MOG 
or MBP 
 
A number of published studies have shown that antibodies specific for MOG and 
MBP are present in the serum and CSF of MS patients (Karni et al. 1999; Lindert et 
al. 1999; Mantegazza et al. 2004; Markovic et al. 2003; Reindl et al. 1999; Sun et al. 
1991; Xiao et al. 1991). We therefore evaluated if any of our nine MS-mAbs is 
reactive with one of these two myelin antigens.  We performed ELISA experiments 
with the recombinant extracellular domain of human MOG produced in E.coli and with 
purified human MBP. No reactivity could be demonstrated for any of the tested 
antibodies (Fig. 13A).  As it has been shown that antibodies against glycosylated 
epitopes of MOG possess myelin destructive potential (Marta et al. 2005) we also 
tested our antibodies in FACS analysis with eukaryotic cells transfected to express 
native human MOG on their surface (Fig. 13B).  As was the case for the ELISAs, no 
reactivity of any of the MS-mAb could be detected.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13:  mAbs derived from cePC do not react with MOG or MBP. Panel A shows ELISA 
experiments demonstrating the lack of reactivity with recombinant MOG or purified human MBP. Panel 
B shows histograms of FACS experiments with a eukaryotic cell line (Jurkat) transfected to express 
human MOG on its surface. Note the clear reactivity (shift to the right) of humanized anti-MOG 8-18c5 
antibody (light grey histogram). In comparison no reactivity of cePC derived MS-mAbs (here: CIS1-40, 
black; identical findings for all other MS-mAbs, not shown) with MOG-expressing Jurkat cells could be 
demonstrated. 
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2.3.3 Antibodies produced by cePC from MS CSF do not react with 
human myelin in western blot and FACS experiments 
 
As outlined above, seven of nine MS CSF derived antibodies (RRMS1-36, CIS1-40, 
CIS1-86, CIS1-92, RRMS2-34, RRMS2-101, SPMS1-61) showed a myelin specific 
immunofluorescence staining on MS lesion tissue. To confirm these findings, we 
performed further experiments using myelin extracted from frozen human MS and 
healthy control brain tissue.   
 
First we performed extensive western blot analysis on large gradient acrylamide gels.  
Figure 14A shows a western blot with different control antibodies confirming a proper 
myelin isolation and western blot experimental set-up. However, no band additional 
to the bands from secondary antibody only could be detected with any of the myelin 
specific MS-mAb (Fig. 14B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Western blot analysis of human myelin extracted from MS and control brain tissue. A. The 
myelin preparations were tested with antibodies specific for myelin associated glycoprotein (MAG), 
cyclic 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) and myelin ologodendrocyte glycoprotein 
(MOG). B. Myelin western blot probed with MS-mAb RRMS2-34. Bands marked with asterisks were 
also present with secondary antibody only (data not shown).  
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There are different possible reasons why these western blot experiments were not 
successful. One possible explanation is that under the denaturating conditions of 
western blot analysis potential epitopes were destroyed. To overcome this problem 
we performed myelin FACS experiments in which the myelin proteins should be in 
their native conformation with all posttranslational modifications. As myelin consists 
of more than 70% lipids, it forms small vesicles if dissolved in a physiological buffer. 
Figure 15 shows FACS stainings of such small myelin vesicles. The only antibody 
demonstrating clear reactivity for the vesicles was MS-mAb RRMS1-6, one of the 
antibodies displaying an astrocyte like immunofluorescence-staining. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: FACS analysis of myelin-vesicles stained with MS-mAb. Forward and side-scatter analysis 
of the vesicles is shown in the upper left panel. The red line in the histograms shows staining of the 
respective mAb, while the blue line represents the isotype control staining. Positive control anti-MOG 
hu8-18c5 shows clear binding. However, from the MS-mAb only mAb-RRMS1-6 binds strongly to the 
myelin-vesicles. X-axis of the histogram shows fluorescence intensity, Y-axis percent of cell counts. 
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Pathogen specificity and autoimmunity are distinct features of 
antigen driven immune responses in neuroborreliosis 
 
Sandra Kuenzle*, Hans-Christian von Büdingen*, Mirjam Meier, Melanie D. Harrer, Eduard 
Urich, Burkhard Becher and Norbert Goebels 
 
* SK and HCVB contributed equally 
 
Infection and Immunity, August 2007, in press. 
 
Abstract: 
Neuroborreliosis (NB) is a chronic infectious disease of the central nervous system 
caused by a tick borne spirochete, Borrelia burgdorferi (Bb). In addition to direct 
effects of the causative infectious agent, additional immune mediated mechanisms 
are thought to play a role in the central nervous system (CNS) pathology of NB. In 
order to further understand the involvement of humoral immune mechanisms in NB, 
we dissected the intrathecal antibody responses down to the single plasma cell level. 
Starting with single cell RT-PCR of FACS sorted cerebrospinal fluid plasma cells from 
a NB patient, we identified expanded clones and resurrected the antigen specificity of 
their secreted antibodies through recombinant expression of the correctly paired Ig 
heavy and light chain genes as monoclonal antibodies (mAb). As expected, we found 
specificity for the causative infectious agent Bb among the clonally expanded plasma 
cell (cePC) derived mAb. However, from an independent cePC of the same patient, 
we could derive mAbs specific for human CNS myelin, without detectable 
crossreactivity with Bb antigens. While reactivity against Bb is a known feature of 
humoral immune responses in NB, we show a) that immune responses specific for 
self-antigens may be a distinct feature of CNS infections independent of pathogen 
reactivity and b) that humoral autoimmunity in NB – since found in cePC - is the 
result of a truly antigen driven immune response. Our findings indicate that in NB 
mechanisms may be at play that induce distinct immune responses specific for 
pathogen and self-antigens independent from “molecular mimicry”. 
 
Original Research Articles  35 
Thesis author work: This manuscript is the thesis core and experiments were 
mainly performed by myself. Contributions from other people comprise part of the 
immunofluorescence experiments and help in preparing the manuscript.  
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Clonally expanded plasma cells in the CSF of MS patients produce 
CNS specific immunoglobulins 
 
Hans-Christian von Büdingen#, Melanie D. Harrer#, Sandra Kuenzle#, Mirjam Meier, Tobias 
A. Rupprecht and Norbert Goebels 
 
# HCVB, MH and SK contributed equally 
 
Submitted. 
 
Abstract: 
Clonally expanded plasma cells (cePC) and their presumed products, oligoclonal 
immunoglobulin bands (OCB), are characteristic findings in the cerebrospinal fluid 
(CSF) of patients with multiple sclerosis (MS). While cePC and OCB strongly suggest 
an involvement of B cell dependent immune mechanisms in the pathogenesis of MS, 
their actual pathological relevance and target antigens remain unknown. To further 
understand the potential role played by cePC we generated a panel of monoclonal 
recombinant antibodies (MS-mAb) from MS CSF-derived cePC from 4 patients with 
early or definite MS. Single cell RT-PCR of correctly paired heavy and light chain 
immunoglobulin genes from individual cePC ensured the subsequent resurrection of 
their original antigen specificity. Immunofluorescent stainings of MS lesion tissue with 
MS-mAbs revealed myelin reactivity in the cePC repertoire of all 4 patients and 
astroglial reactivity in 2 patients. Our findings provide conclusive evidence for the 
presence of an antigen driven B cell response culminating in the expression of CNS 
specific antibodies in the CSF of MS patients. 
 
Thesis author work: I produced some of the MS-mAb. Furthermore I performed the 
FACS experiments. 
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Exploiting the tumor-specific immune response of cancer patients 
for the isolation of tumor antigen specific human monoclonal 
antibodies 
 
Christoph Esslinger*, Sandra Kuenzle*, Irene Abela*, Alfred Zippelius, Dirk Jäger, Alexander 
Knuth, Roger M. Nitsch*, Holger Moch*, and Norbert Goebels* 
 
*CE, SK and IA as well as RMN, HM and NG contributed equally  
 
Submitted. 
 
Abstract: 
Antibodies specific for tumor-associated antigens have been identified in the sera of 
a variety of cancer patients. Their clinical significance however, was difficult to 
assess due to the lack of a straightforward approach for the isolation and cloning of 
patient-derived antibodies. In the present study we describe a method for the 
isolation, molecular cloning and recombinant production of patient-derived human 
antibodies to tumor-associated antigens. This was achieved by screening of 
oligoclonal memory B cell cultures established from patient PBL combined with a 
molecular cloning step using single cell RT-PCR and re-screening of recombinant 
antibody clones.  
In a proof of principle study we cloned a human antibody specific for the tumor-
associated antigen NY-ESO-1 from a melanoma patient who was seropositive for 
NY-ESO-1 in ELISA and on autologous tumor sections. The screening was 
performed on ELISA and on tumor tissue using an adaptation of the tissue micro 
array technology. The obtained tissue-reactive human monoclonal antibody was 
shown to bind to the N-terminus of NY-ESO-1 that is also shared by the tumor-
associated antigen LAGE-1.  
This method greatly facilitates the cloning of patient-derived antibodies; applied to 
selected clinical responders it may lead to the identification and isolation of novel 
candidate antibodies for the immunotherapy of cancer.  
 
Thesis author work: I performed the single cell PCR, cloning and recombinant 
production of the tumor specific monoclonal antibody. Furthermore I performed the 
epitope mapping, the avidity and the immunofluorescence experiments.  
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4 DISCUSSION 
 
4.1 Recombinant antibodies: general considerations 
 
Antibodies play a central role in adaptive mammalian immunity against invading 
pathogens but if erroneously directed against self, they can also lead to and/or 
support autoimmune processes. The key feature of antibodies is their ability to bind 
with high specificity and affinity to their cognate antigen. Antibodies can scavenge 
their target by forming immune-complexes, mediating phagocytosis or recruiting 
cytotoxic systems.  
To date, little is known about the role played by antibodies in the CSF of patients with 
neuroinflammatory diseases. The analysis of the antigen specificity and disease 
relevance of antibody responses in the CSF has been hampered by both the limited 
availability and oligo/polyclonal composition of CSF Ig. Furthermore, CSF contains 
both intrathecally synthesized oligoclonal IgG and blood-derived IgG. However, 
antibodies derived from cePC in the CSF are particularly expected to be disease 
relevant. Our goal was therefore to establish a method to accurately dissect the 
various antigen specificities contained in CSF down to a clonal level and to resurrect 
them in the form of recombinant mAbs. The availability of mAbs would thus provide 
us with appropriate tools for the characterization of both cognate target antigen(s) 
and functional relevance. 
Several technologies have enabled the cloning and isolation of human antibodies 
including different phage display technologies. Such technologies are based on 
random combinatorial pairing of the variable region genes of Ig H and L chains. This 
dissociation of the natural H and L chain pairing may destroy the original specificity 
and may lead to unwanted new specificities. It is therefore important to implement 
methods starting from single antibody producing cells and resurrect their original 
specificity.  
More than 30 years ago, Köhler and Milstein invented the technology for producing 
mAb by immortalizing murine B cells, which earned them the Nobel prize (Kohler and 
Milstein 1975). Alternative techniques for human B cell cloning have been developed, 
such as EBV transformation (Traggiai et al. 2004) or single B cell culture (de Wildt et 
al. 1997; Weitkamp et al. 2003). However, these methods mostly have relatively low 
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cloning efficiencies, are difficult to perform with human B cells and have not been 
successfully used with plasma cells. Therefore they are unsuitable for use when 
handling the limited amount of B cells in the CSF and are clearly inadequate for 
single human plasma cells.  
Following experimental procedures published by others (Owens et al. 2004; 
Wardemann et al. 2003), we established a system to amplify the paired rearranged Ig 
H and L chain genes of individual plasma cells from CSF by single cell RT-PCR. 
Cloning of these amplicons into expression vectors and the use of an eukaryotic 
expression system permitted the production of recombinant human mAb representing 
the original specificity of the isolated single plasma cells.  
In pilot experiments we validated our system. We therefore amplified Ig H and L 
chain V region genes from a hybridoma producing the MOG-specific antibody 8-18c5. 
We cloned these V regions into the same expression system used for plasma cell 
derived antibodies and produced a chimeric hu8-18c5. Competition ELISA 
experiments with the original 8-18c5 and the recombinant hu8-18c5 demonstrated 
that both specificity and affinity are preserved by recombinant expression. 
The methods described herein open new routes for the characterization of plasma 
cell responses in inflammatory CNS disease. They may facilitate the identification of 
potentially disease relevant target antigens recognized by antibodies in the CSF of 
patients with inflammatory CNS diseases.  
Additionally, this experimental strategy may be used to exploit the focused human 
immune response to generate human mAbs of both pathogen and auto-antigen 
specificity, which might be used as therapeutic agents. Since such antibodies are 
matured in the human immune system they may bear advantages of lower 
immunogenicity and “human-like” specificity as compared to mAbs produced in mice. 
Combining the described resurrection of mAb and the cultivation of peripheral 
memory B cells from a cancer patient, we succeeded in the production of a human 
tumor specific antibody (described in Esslinger, Kuenzle et al. submitted). To our 
knowledge, this is the first patient derived tumor specific mAb. The application of this 
technique to selected clinical responders may lead to the identification and isolation 
of novel candidate antibodies for the immunotherapy of cancer.  
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4.2 Clonally expanded plasma cells 
 
The clonal expansion of B cells and their differentiation into plasma cells is a 
characteristic feature of an antigen driven immune response. All members of a 
plasma cell clone bear the same or highly similar Ig sequences as they have 
developed from a single proliferating ancestor B cell. In inflammatory CNS diseases, 
cePC are believed to be the producers of OCB. In infectious CNS diseases, OCB 
have been demonstrated to include specificities to the causative agent (reviewed in 
(Gilden et al. 1996)). Despite the fact that non-clonally expanded plasma cells may 
also produce disease relevant antibodies, as demonstrated by Burgoon et al in SSPE 
(Burgoon et al. 2006), the present study is focused on investigating the humoral 
immune response as expressed by cePC because cePC undoubtedly represent an 
active part of an antigen specific immune response.  
 
CePCs and clonally restricted Ig gene usage can be found in MS CSF and lesion 
tissue cells, respectively (Baranzini et al. 1999; Ritchie et al. 2004). In the present 
study the cePCs were identified as a group of plasma cells bearing identical CDR3 
region sequences.  
The IGHV segments of all cePC derived H chain sequences contained several 
mutations as compared to their most closely related germline sequences, providing 
evidence that affinity maturation including somatic hypermutation has occurred in 
these antibodies.    
Some groups of H chain V regions sharing identical H-CDR3s showed infrequently 
interspersed replacement mutations. The finding of such clonal variants in the CSF 
could be a hint that the CSF/CNS is an environment playing a supporting role for 
affinity maturation in antigen driven B cell responses. Other groups of sequences 
from cePC did not show such replacement mutations but bored Ig gene sequences of 
100% identity. Since a number of precautions had been taken to avoid cross 
contamination between wells of PCR plates (see Materials and Methods), and we 
also obtained several "unique" sequences from single plasma cells analyzed in the 
same PCR experiment, we expect that sequences of 100% homology are not a 
product of contamination. Also the fact that we obtained identical Ig L chain 
sequences from the plasma cells bearing identical Ig H chain sequences make a 
“dual” cross-contamination extremely unlikely. 
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4.3 Recombinant antibodies from clonally expanded CSF plasma 
cells from a neuroborreliosis patient  
4.3.1 Borrelia specific antibody mAb-RA77 
4.3.1.1 Proof of principle 
 
One (RA77) of the human mAbs derived from cePCs in the CSF of a patient with NB 
specifically reacted with Bb, the causative infectious agent of NB. ELISA experiments 
with different Bb strains demonstrated that mAb-RA77 binds to all tested Bb strains 
and does not cross-react with E.coli.  Immunofluorescence stainings of Bb confirmed 
Bb specificity of mAb-RA77. To exclude cross-reactivity of mAb-RA77 with other 
spirochete bacteria we also evaluated possible binding to Tp. No binding to Tp could 
be detected again confirming Bb-specificity of mAb-RA77.  
This finding of a Bb specific antibody produced by a cePC is consistent with previous 
studies showing that OCB in the CSF of NB patients contain antibodies directed 
against Bb (Hansen et al. 1990; Martin et al. 1988a). This finding is also consistent 
with recent data from our laboratory confirming that cePC are in fact the producers of 
OCB (unpublished data). To date, the only other inflammatory disease for which a 
link between antibodies expressed by CNS derived plasma cells and the causative 
agent has been demonstrated is SSPE: Burgoon et al. obtained measles virus-
specific antibodies from individual plasma cells excised from post mortem brain 
tissue of a patient with SSPE by laser capture microdissection (Burgoon et al. 2005). 
In contrast to infectious CNS disease, the antigen specificity and pathogenic role of 
OCB in presumed autoimmune conditions such as MS remains to be defined.  
The successful generation of the pathogen specific mAb-RA77 from a single CSF 
plasma cell demonstrates that the method described here accurately resurrects the 
antigen specificity of the original plasma cell. It validates the utility of the described 
technical approach for the characterization of plasma cell responses in inflammatory 
diseases.  
This proof of principle was important as we also applied this approach for 
investigating the unknown origin of the humoral immune response in MS.  Exploiting 
the described technique could lead to the identification of disease relevant target 
antigens in MS. First steps toward this goal are described in section 2.3 and in von 
Büdingen, Harrer, Kuenzle et al., submitted.  
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4.3.1.2 Further characterization of mAb-RA77 
 
To further analyze the exact antigen specificity of the Bb reactive RA77 mAb, We 
performed immunoprecipitation and subsequent MALDI-TOF analysis. We were 
thereby able to identify the cognate antigen of RA77, namely the Bb flagellum protein 
p41. While We found a high affinity interaction between antibody RA77 and native Bb 
lysate, its affinity to recombinant p41 protein was significantly lower. This finding 
suggests that the interaction between RA77 and native p41 may not only depend on 
its amino acid sequence, but also on conformation and potential posttranslational 
modifications. Such modifications have been demonstrated in flagellum proteins of 
other spirochetes (Brahamsha and Greenberg 1988; Li et al. 1993; Wyss 1998). 
Another explanation for the lower affinity of antibody RA77 for the recombinant p41 
protein as compared with the native protein may be partial misfolding of the 
recombinant protein. Nevertheless, the high affinity interaction between RA77 and 
native Bb lysate suggests that RA77 is the result of an affinity matured antibody 
response.  
 
4.3.2 Myelin specific antibody mAb-RA17 
 
Besides the immune response to Bb, analysis of the immune response in the CSF of 
patients with NB has also revealed auto-antibodies to CNS proteins (Kaiser 1995) 
and T cells recognizing peptides derived from CNS specific auto-antigens (Hemmer 
et al. 1999; Lunemann et al. 2006). Such auto-aggressive immune cells could 
contribute to the CNS tissue damage observed in some NB patients. We tested the 
cePC derived mAb for possible reactivity with auto-antigens.  Because the patient, 
whose cePC were used in this study, suffered from facial nerve palsy, a common 
clinical presentation of NB, we first investigated a possible specificity of RA17, RA20 
and RA77 for facial nerve tissue.  
 
Interestingly, one of these antibodies, RA17 displayed reactivity with this tissue. To 
further evaluate the tissue components RA17 is specific for, we performed double 
immunofluorescence stainings with a myelin specific antibody (8-18c5), which 
strongly suggested myelin reactivity of RA17. Although not completely overlapping, 
co-staining of the 8-18c5 antibody and RA17 indicated reactivity with identical 
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structures, representing myelin. However, myelin reactivity of RA17 was not limited to 
facial nerve tissue but could also be detected in CNS white matter myelin. Double 
stainings with RA17 and a neurofilament specific antibody indirectly confirmed this 
notion, as RA17 stained structures enfolding neurons. Immunofluorescence stainings 
with RA17 on a number of different control human tissues (colon, kidney, lung) 
yielded negative results, suggesting CNS restricted reactivity.  
Whether the appearance of the RA17 mAb actually bears immunopathological 
significance will be the subject of further studies. However, as diffuse white matter 
lesions are frequently observed in NB there might be a contribution of such auto-
reactive antibodies to myelin damage.  
 
4.3.3 Distinct immune responses – no molecular mimicry 
 
Our findings suggest that aside from pathogen directed humoral immune responses, 
immunopathological mechanisms occurring in CNS infectious disease may also 
evoke autoimmunity. Various Bb specific antibodies cross-reacting with CNS auto-
antigens have been described (Alaedini and Latov 2005; Dai et al. 1993). These 
studies support the hypothesis that autoimmunity due to molecular mimicry may play 
a role in NB. Hypothetically, molecular mimicry mechanisms would be due to 
Borrelia-specific epitopes shared with human tissue and are known to be important in 
the progression of Lyme arthritis (Gross et al. 1998). However, as neither Borrelia 
specific mAb RA77 reacts with human tissue nor auto-reactive RA17 with Borrelia no 
such molecular mimicry mechanisms could be described in the present study. We 
rather provide evidence that in NB additional mechanisms, eliciting distinct immune 
responses for pathogen and self-antigens may be at play.  
This novel finding could be delineated by the use of the described single cell 
approach. As we reconstructed the antigen specificities of antibodies secreted by 
individual expanded CSF plasma cell clones, we were able to dissect the complex 
repertoires of the adaptive humoral immune system in response to CNS infection with 
Bb. 
Interestingly, not only the Bb specific but also the auto-reactive antibodies were 
originally produced by cePC. This demonstrates that in NB humoral autoimmunity 
can also be the result of a truly antigen driven immune response. However, as 
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mentioned above, the immunopathological relevance of such auto-reactive 
antibodies remains still elusive.  
 
 
4.4 Recombinant antibodies from clonally expanded CSF plasma 
cells from MS patients  
 
OCB are a hallmark feature of MS CSF but their pathological role still remains 
elusive. A first step towards a better understanding of immune responses in MS 
would be the identification of the specificity of these Ig.  
A number of studies have investigated the Ig in the CSF of MS patients; among 
others, reactivity to the auto-antigen MOG (Xiao et al. 1991) and to viral proteins of 
EBV (Cepok et al. 2005) have been described. Focusing on the antigen driven 
immune responses, other investigators have found an axon-directed antibody 
response by analyzing recombinant antibodies constructed from CSF B cell clones 
(Zhang et al. 2005) and OCB specific for Chlamydia pneunomia have also been 
described (Franciotta et al. 2005). 
By applying the herein described and validated approach for the production of mAbs 
from cePC, we produced nine recombinant mAbs from plasma cell clones in the CSF 
of four MS patients. To determine their cognate antigen we applied a number of 
experimental approaches. A rather large effort was undertaken using clones of a 
human fetal brain cDNA expression library spotted on nitrocellulose membranes. 
Incubation of this library with our MS-mAbs resulted in a number of potential target 
antigens, which when tested in purified form did not turn out to be high affinity 
targets, suggesting that these findings are rather due to non-specific binding. There 
are a number of different possible explanations why this approach failed. As the 
proteins of this library are expressed in E.coli, posttranslational modifications are 
absent and intact conformation is not assured. However, such attributions could be 
important in antibody antigen complex formation. Another possible reason for the 
negative results of these experiments is that the library is derived from fetal human 
brain (week 14 post fertilization) cDNA. At that developmental stage, axons of the 
human brain have not undergone myelination, therefore myelin proteins are not yet 
expressed and will not be represented in this cDNA library. Because, as was later 
shown in immunofluorescence experiments performed by my colleague Melanie 
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Harrer, most of our MS-mAbs bind to myelin, a positive result from this brain cDNA 
library seems unlikely.  
 
As mentioned, seven of nine MS-mAb react with CNS myelin and two with astroglia. 
Most prominently, the seven myelin reactive MS-mAbs bound to myelin at the rim of 
MS lesions. Myelin destruction is a major histopathological feature of MS and has 
been strongly associated with the humoral immune response. Namely, antibody and 
complement depositions have been described in areas of myelin destruction 
(Lucchinetti et al. 2000; Storch et al. 1998) and MOG-specific antibodies have been 
found in areas of active myelin disintegration (Genain et al. 1999). However, whether 
antibodies detecting myelin proteins in the serum of MS patients can be used as 
diagnostic or prognostic markers for MS or wheter they play a role in the 
pathogenesis of MS remains a matter of debate (Berger et al. 2003; Kuhle et al. 
2007).  
 
The finding of antibodies derived from MS CSF cePC actually recognizing CNS 
myelin indicates that an antigen driven immune response against myelin proteins 
takes place in the CNS compartment of MS patients. To determine the antigen 
specificity, an obvious first choice was to examine whether our MS-mAb displayed 
specificity for the commonly studied CNS myelin antigens MOG and MBP.  
No reactivity with MBP (purified from human brain) or recombinant MOG could be 
detected in ELISA experiments. As recent research demonstrated that antibody 
responses against glycosylated epitopes of MOG possess myelin destructive 
potential (Marta et al. 2005) we also tested reactivity to eukaryotic cells (Jurkat) 
transfected to express native human MOG on their surface. No reactivity of any MS-
mAb could be demonstrated by FACS analyses.  
In a next step we performed western blotting experiments using a myelin extract 
made from a post mortem MS patient brain. However, no specific reactivity could be 
detected for any of the MS-mAb reacting with myelin in immunofluorescence 
experiments. Because it is known that pathogenic antibodies often recognize 
conformation dependent epitopes (von Budingen et al. 2004), this negative result 
could be due to the denaturating conditions used in western blotting. We therefore 
performed FACS experiment with myelin vesicles stained with our MS-mAb. As these 
vesicles are formed in physiological buffer myelin proteins would be expected to be 
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present in their native conformation with all posttranslational modifications present. In 
spite of this, no significant binding of MS-mAbs to myelin vesicles could be detected. 
The reason for the fact that only immunofluorescence experiments were able to 
reveal myelin specificity of MS-mAbs remains undetermined. However, it could be 
that the antigen is somehow omitted from the myelin preparation or not abundant 
enough to be detected in the techniques employed. As the immunofluorescence 
staining is most pronounced at the rim of MS lesions, it could be that the antigen is 
only expressed in such restricted areas. If this was the case, the concentration of the 
antigen would be very small in a whole myelin preparation.  
 
4.4.1 Possible explanations why we failed so far in identifying the 
cognate antigens 
 
Even after using various experimental approaches, so far we have been 
unsuccessful in the identification of the cognate antigens of the auto-reactive mAb 
from CSF cePC. In that context it is of interest to note that another recent study, 
employing random peptide libraries, also failed to identify potential target antigens of 
mAb derived from MS CSF cePC (Yu et al. 2006).  
 
Several different explanations are possible for these difficulties: 
 
1. Specificity of MS-mAbs for epitopes involving lipids: CNS lipids have been 
described to be target antigens of the humoral immune response in MS (Kanter et al. 
2006; Menge et al. 2005). However, so far no experiments appropriate for the 
detection of lipid-epitopes have been conducted. 
 
2. Specificity for epitopes involving posttranslational modifications: Post-translational 
modifications of proteins occur very frequently and several hundred different ones are 
known. The role played by these modifications is poorly understood at this time. 
However, post-translational modifications may determine the nature and extent of 
secondary and tertiary structure, permitting the protein to adopt multiple 
conformations and thus providing possible targets for autoimmune responses. 
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Recent studies established that MBP from MS brain is less phosphorylated and more 
methylated compared to MBP from normal brain (Kim et al. 2003). Furthermore it has 
been demonstrated that in MS brain MBP is more citrullinated (Moscarello et al. 
1994) and the operating enzyme converting arginine to citrulline (peptidylarginine 
deiminase) has been shown to be upregulated (Moscarello et al. 2007). The 
relevance of such differences in post-translational modifications remains to be 
elucidated. However, serum antibodies reactive to citrullinated proteins/peptides have 
been shown to be a specific marker for the autoimmune disease rheumatoid arthritis 
(Migliorini et al. 2005). It is possible that in the approaches we used to investigate the 
antigen(s) recognized by our mAbs, such novel autoimmune epitopes generated by 
particular post-translational modifications were absent.  
 
3. Specificity for polysaccharide and/or carbohydrate moieties: Another possibility 
would be that our mAbs specifically recognize molecules with glycosidic bonds 
involving sugars (polysaccharides or carbohydrates), so called glycans. Recent 
studies have demonstrated increased serum anti-Glc(alpha1,4)Glc(alpha) (Schwarz 
et al. 2006) and anti-N-glycosylated peptide (Lolli et al. 2005) antibodies in relapsing-
remitting MS patients. The latter study could even show via immunohistochemistry of 
brain tissue, that these anti-N-glycosylated peptide antibodies recognize myelin and 
oligodendrocyte auto-antigens. Though most of these anti-glycan antibodies are of 
IgM isotype, it would be interesting to test whether our MS-mAb obtained from IgG 
producing cePC possibly recognize such epitopes.  
 
4. Specificity for viruses – molecular mimicry: Viruses have been associated with MS 
for many years and several viruses have been isolated from brains of MS patients 
(Fujinami et al. 2006). Recent work suggests a humoral immune response directed 
against EBV to be a dominant feature of OCB (Cepok et al. 2005). Thus, we had our 
MS-mAbs tested for reactivity against seven common candidate viruses (EBV, CMV, 
HSV, HHV-6, measles, rubella, VZV), yielding negative results. However, it is 
possible that our MS-mAbs are targeting so far unknown viral agents underlying MS 
disease. If this was the case, the identification of the cognate antigens of our MS-
mAbs would be an exceedingly difficult task and methods like those applied by Yu et 
al. (Yu et al. 2006) may ultimately be successful. Nevertheless, even if our MS-mAbs 
were the result of an initial immune response against an infectious agent and cross-
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react with CNS myelin, it would be interesting to know the viral antigen but at the 
same time it should be possible to identify the myelin antigen. 
 
5. Low affinity of MS-mAb: As the MS-mAbs available in our lab are the result of an 
antigen driven immune response and show clear signs of having undergone affinity 
maturation, we presume them to be of high affinity.  However, they also exhibited an 
unexpectedly low affinity, which would make the determination of their cognate 
antigen extremely difficult or even impossible with the applied methods.  
 
 
4.5 Relevance of self-reactive antibodies in the context of 
autoimmunity 
 
We describe here auto-antibodies reacting with CNS myelin in the repertoire of CSF 
cePC in NB and MS patients. It is known that auto-antibodies are present in these 
diseases, however their relevance is a matter of debate as antibodies against myelin 
auto-antigens have also been described in healthy control subjects (Karni et al. 1999; 
Lindert et al. 1999; Mantegazza et al. 2004; Markovic et al. 2003; Reindl et al. 1999; 
Sun et al. 1991; Xiao et al. 1991).  
However, the auto-antibodies described in this study were originally secreted by 
cePC and therefore the product of a truly antigen driven immune response. This 
indicates that reactivity to self-epitopes can be the result of a focused immune 
response in the CNS compartment of patients with inflammatory CNS diseases.  
 
One of the key questions in the study of the immune response is how the normal 
tolerance to self-proteins is broken leading to the induction of autoimmunity. Negative 
selection deletes self-reactive immune cells during their development. However, the 
maintenance of tolerance to peripheral self-proteins or newly arising self-epitopes is 
not fully understood. Different processes can modify self-proteins thereby creating 
neo-self antigens to which the immune system has never been exposed or tolerated 
in the periphery.  
Several post-translational modifications can create such new self-antigens and some 
of them have been shown to be associated with autoimmune responses (Doyle and 
Mamula 2001; Mantegazza et al. 2004).  
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Recent findings implicate apoptotic cell death in the evolution of autoimmunity 
(Mahoney and Rosen 2005). On the one hand, apoptotic cells play an important role 
in maintaining tolerance to auto-antigens and abnormalities in this process may lead 
to systemic autoimmunity. On the other, ‘non-default’ forms of apoptotic death can 
also generate new self-antigens, thus initiating immune responses.  
Another explanation for the emergence of the observed auto-reactive plasma cells 
would be a mechanism of molecular mimicry as previously demonstrated for T cells 
in MS (Wucherpfennig and Strominger 1995). Yet, no known viral agent cross-
reacting with the auto-specific MS-mAb could be identified. Although it is thought that 
in NB molecular mimicry plays a role in immune responses, no such cross-reaction 
could be determined in the present study.  
 
At present, the immunopathological role of the auto-reactive antibodies described 
here remains cryptic. Also it is not known if these antibodies are the result of a 
primary or secondary effect. On the one hand, they may possess a primary 
demyelinating activity in the context of a CNS-directed inflammatory response. Data 
from animal models of MS, including rodent (Schluesener et al. 1987) and primate 
(Genain et al. 1995) EAE have long suggested an involvement of myelin directed 
antibodies in pathological processes leading to demyelination. On the other, they 
possibly have a scavenging activity in an environment where inflammation and 
myelin breakdown leaves cellular debris to be removed. 
 
It is difficult to judge whether an infection, a neurodegenerative process or a genuine 
autoimmune reaction is the initial event in MS disease. The fact that binding of mAbs 
from cePC is largely restricted to the border of demyelinating lesions, could be 
interpreted as a hint for an immune response specific for novel epitopes evolving 
during tissue destruction, rather than a primary demyelinating one. However, the 
elucidation of the antigen specificity would be indispensable information to judge the 
relevance of these antibodies.  
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5 MATERIAL AND METHODS 
5.1 Standard buffers 
 
PBS 150mM NaCl 
 30mM  KCl 
 1.5mM  KH2PO4
 6mM  Na2HPO4
 
 
TBS 10mM Tris/HCL pH: 8.0 
 150mM NaCl 
 
 
LB 1 % (w/v) Bacto Trypton  
 0.5 % (w/v) Hefeextrakt  
 0.5 % (w/v) NaCl  
 
5.2 Patients, cerebrospinal fluid and plasma cell sorting 
 
Upon receiving informed consent from each patient, we obtained 7-10 ml of CSF 
during a spinal tap intended for diagnostic purposes. The study was approved by the 
local ethics committee. CSF cells were incubated with FITC labeled anti-human 
CD138 monoclonal antibody (Serotec) at 4 °C for 20 minutes. Single CD138+ plasma 
cells were sorted on a FACS-Aria (Becton Dickinson) into individual wells of 96-well 
PCR plates, each containing 20µl of reverse-transcription reaction buffer and stored 
at -80 °C until further processing. 
 
5.3 Single cell-RT-PCR and antibody cloning 
 
For initial single cell RT-PCR, reverse primers specific for the constant regions of Ig 
genes (IgG-heavy chain, λL chain, κL chain) and forward primers specific for the 
conserved framework region 1 complementary for H or L chain Ig variable region 
families were used, as described (Andris-Widhopf et al. 2001; Owens et al. 2003). 
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PCR products were resolved on a 1.2% agarose gel. Appropriately sized PCR 
products were extracted from agarose gels and sent for automated sequencing 
(Synergene Biotech). Ig sequences from cePCs were identified by assembling 
groups of identical Ig H chain V region genes (SeqMan, DNASTAR) and were further 
analyzed for germline segment usage and H-CDR3 mutations via the V-Quest tool on 
the IMGT website (Giudicelli et al. 2004).  
H and L chain V region genes of the MOG-specific antibody 8-18c5 were amplified 
from 8-18c5 hybridoma cells (kindly provided by C. Linington, University of Aberdeen, 
Scottland) mRNA by RT-PCR using mouse Ig specific primers (Breithaupt et al. 
2003) and cloned into the expression vectors described later on to obtain chimeric 
anti-MOG antibodies containing the murine antigen binding region of 8-18c5 and a 
human IgG1 Fc-portion (hu8-18c5).  
To avoid PCR cross-contamination between different patients’ repertoires and to rule 
out contamination of PCR components, we took a number of precautions: 1. A 
number of negative controls, e.g. wells of PCR plates in which no plasma cells had 
been deposited, were run on each PCR plate; 2. The areas in which PCR setup, PCR 
analysis by gel electrophoresis and cloning of PCR products were performed, are 
designated spaces, which are physically separated and equipped with designated 
sets of pipetters; 3. Fresh aliquots of PCR components were used for each patient’s 
CSF plasma cell repertoire.  
Ig H and L chain PCR products from cePC were cloned into vectors containing the 
constant region of IgG1, Igκ or Igλ (kindly provided by H. Wardemann, Max-Planck 
Institut für Infektionsbiologie, Berlin, Germany) as described (Wardemann et al. 
2003). Briefly, for cloning IgH and Igλ genes, restriction sites were introduced by the 
2nd PCR. Digested IgH and Igλ PCR products were gel-purified and directly cloned 
into expression vectors containing human IgG1 or Igλ constant regions. Igκ 2nd-PCR 
reactions were performed with a consensus κ primer and did not allow direct cloning. 
Instead, after sequencing, 1 μl of the purified 1st round RT-PCR product was used 
for a 2nd round of PCR with restriction-site containing specific κ-gene primers. After 
purification, digestion and gel-purification, Igκ PCR products were cloned into the Igκ 
expression vector containing the Igκ constant regions. Plasmids were sequenced to 
select clones with inserts identical to the original PCR product. 
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5.4 Antibody production and purification 
 
293-T human embryonic kidney fibroblasts (ATCC) were cultured in D-MEM 
supplemented with ultra-low IgG FCS, penicillin-streptomycin and L-glutamin (all from 
Invitrogen). Co-transfection of 293-T cells with Ig H and L chain encoding plasmid 
DNA was performed by calcium phosphate precipitation (Chen and Okayama 1988). 
Thereafter the cells were cultured in serum free D-MEM supplemented with 1% 
Nutridoma SP (Roche). Supernatants were collected after 8 days of culture and 
recombinant mAbs (IgG1) were purified by affinity chromatography over protein G 
columns (Amersham Biosciences). Murine hybridoma 8-18c5 (m8-18c5) was a kind 
gift of C. Linington, University of Aberdeen, Scottland. Where desired, antibodies 
were biotinylated using NHS-biotin (Sigma) following the manufacturer’s instructions. 
 
5.5 Western analysis of high-density protein macroarrays 
 
A hEx1 protein array comprising expression products of 37.000 independent human 
fetal brain cDNA clones was obtained from the Deutsches Ressourcenzentrum für 
Genomforschung GmbH (RZPD) (http://www.rzpd.de) and probed with mAb 
according to the manufacturer's recommendations. Briefly, macroarrays were rinsed 
in 96% Ethanol at RT and subsequently washed with water following by TBS, 0.005% 
Tween20, 0.5% Triton X-100 and lastly with TBS. Macroarrays were then blocked for 
2h at RT with 1% milk TBS, 0.5% Tween20. mAbs were added to the blocking 
solution at 10ug/ml and the arrays were incubated o.n. at 4°C. After washing with 
TBS, 0.5% Tween20, anti human IgG-AP (1:5’000, SIGMA) in blocking solution was 
added and incubated at RT for 2h. After washing, positive spots were visualized 
using ECF substrate (Amersham Biosciences) and subsequently scanned on 
FluorImager595 (Molecular Dynamics).  
 
5.6 Expression and purification of His-tag proteins from RZPD 
 
Proteins were purified under denaturating conditions using standard protocols 
(described in detail in Ni-NTA Spin Handbook from QIAGEN). Briefly, rzpd-clones 
were cultured in LB medium containing 100ug/ml ampicilin and 25ug/ml kanamycin at 
37°C with vigorous shaking until the OD600 reached 0.6. Then, IPTG was added to a 
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final concentration of 1mM and the culture was grown for further 4 hours. Cells were 
harvested by centrifugation and resuspended in 8M urea, 0.1M NaH2PO4, 0.01M 
Tris-Cl pH 8 (buffer B). They were then incubated for 1 hour at RT with agitation and 
subsequently, the lysed cells were centrifugated (30 min, RT, 10’000g) to pellet the 
cellular debris. After equilibration of Ni-NTA spin column with buffer B, the cleared 
lysate supernatant was added. Columns were washed with 8M urea, 0.1M NaH2PO4, 
0.01M Tris-Cl pH 6.3 and subsequently, proteins were eluted with 8M urea, 0.1M 
NaH2PO4, 0.01M Tris-Cl pH 4.5.  
 
5.7 ELISA 
 
Wells of polycarbonate plates (MaxiSorp, Nunc) were coated with respective protein 
o.n. at 4°C. Wells were then blocked with PBS containing 0.05% Tween-20 (PBS-T) 
and 3% BSA (SIGMA). Antibodies were added at 10ug/ml in blocking buffer and 
incubated for 1 hour at 37 °C. Bound antibody was detected with a HRP labeled 
secondary antibody, revealed by tetramethylbenzidine (Pierce) and analyzed at 
450nm using a microplate reader (Bio-Rad).  
Coated proteins 
Borrelia-ELISA: 5ug/well Bb protein lysate (kindly provided by Dr. O. Péter, Division 
de Médecine Préventive Hospitalière, Lausanne, Switzerland.)  
p41-ELISA: 0.25ug/well purified recombinant Borrelia afzelii p41 antigen (PKo) 
(Mikrogen) 
E.coli-ELISA: 5ug/well E.coli lysate  
MOG-ELISA: 1ug/well of a recombinant form of the extracellular domain of human 
MOG (rMOG, kind gift of M. Reindl, Innsbruck Medical University, Austria) 
MBP-ELISA: 1ug/well of purified human MBP 
RZPD-protein ELISA: 1ug/well purified RZPD-protein  
Primary antibodies
Recombinant human monoclonal antibodies: 10ug/ml 
Chimeric anti-MOG hu8-18c5-antibody: 10ug/ml 
Rat anti-MBP antibody (Serotec): 10ug/ml 
Secondary antibodies 
HRP labeled goat anti-human IgG+IgM (1:100'000, Jackson ImmunoResearch) 
HRP labeled goat anti-rat IgG antibody (1:50'000 Jackson ImmunoResearch)  
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Streptavidin-HRP conjugate (1:500, SIGMA) 
 
5.8 Competition Assays 
 
Initially, saturation experiments were conducted to obtain the half-maximal binding 
capacity of biotinylated RA77 for 5ug Bb lysate and 0.25 ug recombinant p41, as well 
as of biotinylated 8-18c5. ELISA plates were coated with 5ug/well Bb lysate, 
0.25ug/well recombinant p41 or 1ug/well rMOG and incubated with increasing 
concentrations of biotinylated RA77 or both hybridoma derived (m8-18c5) and 
recombinant chimeric 8-18c5 (hu8-18c5), respectively. Bound biotinylated antibodies 
were detected with streptavidin-HRP and TMB as described above. Competition 
experiments of biotinylated versus non-biotinylated antibodies were conducted to 
obtain the affinity of RA77 for Bb lysate or recombinant p41, and m8-18c5 or hu8-
18c5 for rMOG. Increasing concentrations of non-biotinylated antibodies were added 
to ELISA wells coated with the respective antigens in the presence of the previously 
determined 50% saturation concentration of the corresponding biotinylated antibody. 
After 1 hour at 37 °C, wells were washed and bound biotinylated antibodies detected 
by streptavidin-HRP and TMB. The affinity (Ki) was calculated according to Cheng 
and Prusoff (Cheng and Prusoff 1973). 
 
5.9 Immunoprecipitation 
 
Protein G sepharose (Amersham) was incubated with RA77 or human IgG1 in PBS 
for 3 hours at 4 °C. The sepharose-antibody complex was washed once and 
resuspended in IP-buffer (20mM HEPES, 5mM MgCl, 0.05% NP40, 120mM NaCl, 
and protease inhibitors (Roche)) and Bb lysate was added. Reactions were incubated 
overnight at 4 °C, centrifuged at 500g and resuspended in IP-buffer. The 
resuspended sepharose was added onto pre-equilibrated empty columns 
(Amersham) and washed with IP buffer. Immunoprecipitated proteins were eluted 
with 0.1M glycine buffer pH 3 and separated by reducing SDS/PAGE. Proteins were 
visualized by silver staining (Pierce). Bands for MALDI-TOF analysis were excised 
from duplicate gels stained with Coomassie Blue (Pierce). 
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5.10  MALDI-TOF Analysis 
 
MALDI-TOF analyses were performed by Dr. S. Chesnov and Dr. P. Hunziker 
(University of Zurich, Functional Genomics Center Zurich). Gel bands were cut in 
small pieces. In-gel digestion was performed according to Schrimpf et al. (Schrimpf et 
al. 2001) by re-hydrating the washed and dried gel pieces with 20 µl trypsin solution 
(modified trypsin, Promega). After digestion over night at 37°C the supernatant was 
removed and the gel pieces were extracted with 20µl 5% (v/v) formic acid. 1µl of the 
combined supernatants was mixed with 1µl of a saturated solution of alpha-cyano-4-
hydroxycinnamic acid (Fluka) in 0.1% (v/v) trifluoroacetic acid/acetonitrile (2:1) and 1 
µl was applied onto the MALDI target. Mass spectra were recorded on a Biflex III 
(Bruker Daltonics). The resulting list of peptide masses was searched against MSDB 
protein database using Mascot (http://www.matrixscience.com). 
 
5.11  Immunofluorescence stainings 
 
Bb and Tp spirochetes attached to microscopy slides (Euroimmun) were stained with 
RA77-Biotin and either Bb specific anti-p41 antibody (mAb 1 C11, kindly provided by 
Dr. Fingerle, Munich) or anti-Tp positive human control serum (Euroimmun), 
respectively.  Immunofluorescence stainings of frozen human tissue were performed 
with biotinylated RA17, RA20, RA77 and human IgG (Fitzgerald) on sections of post-
mortem white matter, facial nerve, colon, lung, and kidney tissue (kindly provided by 
the NICHD Brain and Tissue bank for Developmental Disorders under contracts N01-
HD-4-3368 and N01-HD-4-3383) with 10µg/ml per mAb. Sections were fixed with 
formaldehyde, permeabilized with Triton X-100, treated with an avidin-biotin blocking 
protocol (Vectorlabs) and blocked with 10% normal goat serum in PBS supplemented 
with 0.2% Triton X-100. Subsequent incubation with individual biotinylated mAbs took 
place overnight at 4°C, if designated, along with antibodies for simultaneous staining 
of CNS resident cell types (mouse anti-neurofilament200 (SIGMA), neurons; mouse 
anti-MOG 8-18c5-Ab, myelin). After washes in PBS, bound biotinylated mAbs were 
detected with streptavidin-ALEXA546, streptavidin-ALEXA488, anti-mouse IgG-
ALEXA488, anti-mouse IgG-ALEXA546 or anti-humanIgG-ALEXA546 conjugates 
(1:700, Molecular Probes) as secondary antibodies. Nuclei were counterstained with 
Hoechst 55432 and tissue sections mounted with an aqueous mounting medium.  
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5.12  Isolation of human myelin  
 
Human CNS white matter tissue was obtained at autopsy from individuals without a 
history of neurological disease (A00-329 from N. Schaeren-Wiemers) or MS (1709 
kindly provided by the NICHD Brain and Tissue bank for Developmental Disorders 
under contracts N01-HD-4-3368 and N01-HD-4-3383).  
Myelin was isolated as described (Norton and Poduslo 1973), with adaptations. 
Briefly, CNS white matter was homogenized in 0.25M sucrose in 10mM Hepes, 2mM 
EGTA  pH 7.4. After centrifugation, 2M sucrose prepared in 10mM Hepes, 2mM 
EGTA pH 7.4 was added to the supernatant to finally yield a 1.4M sucrose 
suspension. A gradient was set up as following: 0.7ml of 0.25M sucrose, 2ml of 
0.85M sucrose, 9ml homogenate suspension, 1ml of 2M sucrose. Ultracentrifugation 
was performed for 20 hours at 4°C at 25'000rpm. The white cloudy layer obtained on 
the top, containing the compact myelin, was again homogenized in 10mM Hepes, 
2mM EGTA and centrifuged at 25'000rpm for 2 hours at 4°C. After removal of the 
lipid rich layer from the top, supernatant was decanted and the pellet resolved in 
sterile water. Myelin was collected and stored at − 80 °C until further use. The protein 
concentration was calculated using a BSA standard curve by Bradford's method 
(Pierce). 
 
5.13  Myelin western blot 
 
20ug myelin was loaded on a gradient acryl amid gel and run over night at 18V. 
Transfer onto Immuno-Blot PVDF 0,2um membrane (Biorad) was performed at 50V 
in a 192mM Glycine, 25mM Tris buffer. Membranes were blocked for 2 hours at RT 
with 3% TOP-Block (Fluka) in TBS, 0.05% Tween20. mAbs, anti-MAG antibody 
(produced by Anthony Heape, Finland) and anti-CNPase antibody (Covance) were 
incubated at a concentration of 10ug/ml in 1% TOP-Block, TBS, 0.05% Tween20 
over night at 4°C. Secondary anti-human IgG conjugated to IRDye®700DX 
(Rockland Immunochemicals), anti-mouse IgG-ALEXA680 (Molecular Probes) and 
anti-rabbit IgG IRDye®800DX (Rockland Immunochemicals) were diluted 1:2'500 in 
1% TOP-Block, TBS, 0.05% Tween20 and fluorescence signals were measured 
using the Odyssey® Infrared Imaging System (LI-COR Bioscience). 
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5.14  FACS analysis of myelin vesicles 
 
FACS experiments with human myelin was performed as described (Breij et al. 
2006). Briefly, human myelin (15ug) and 1ug of biotinylated mAb or hu8-18c5 were 
added to 100ul PBS pH 7.4 in a 96-well V-bottom plate and incubated overnight at 
4°C. Unbound antibodies were removed by washing the myelin in PBS (4500rpm, 
4min, 3x). Myelin was subsequently incubated with Streptavidin-APC (1:10’000, BD 
Bioscience) for 30 min at 4°C. After washing in PBS (4500rpm, 4 min, 3x) the myelin 
was diluted in PBS, 0.5%BSA and analyzed using a FACS Calibur (BD Bioscience).  
 
5.15  FACS analysis of MOG transfected Jurkat cells 
 
Jurkat cells were stably transfected using Lipofectamine (Invitrogen) to express 
human MOG on their surface (plasmid kind gift of M. Reindl, Innsbruck Medical 
University, Austria). For FACS analysis, MOG-transfected Jurkat cells were 
incubated with 10µg/ml of each MS-mAb, chimeric anti-MOG hu8-18c5-antibody or 
human IgG1 isotype control for 10 min at 4°C. After a wash, bound antibodies were 
detected by addition of anti-human IgG-APC conjugate (BD Biosciences) scanning in 
a FACS Calibur (BD Biosciences). 
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7 ABBREVIATIONS 
 
BAFF  B cell activating factor of the tumor necrosis factor family 
Bb  Borrelia burgdorferi 
BSA  Bovine serum albumin 
C  Constant 
CD  Cluster of differentiation 
CDR  Complementarity-determining region 
cePC  Clonally expanded plasma cells  
CIS  Clinically isolated symptom 
CMV  Cytomegalievirus 
CNS  Central nervous system 
CSF  Cerebrospinal fluid 
DNA  Deoxyribonucleic acid 
EAE  Experimental autoimmune encephalomyelitis 
E.coli  Escherichia coli 
EBV  Ebstein-Barr virus 
ELISA  Enzyme linked immunosorbent assay 
FACS  Fluorescence activated cell sorting 
H  Heavy 
HHV-6 Human herpesvirus-6  
HRP  Horse radish peroxidase 
HSV  Herpes simplex virus 
Ig  Immunoglobulin 
IL  Interleukin 
L  Light 
LFA-1  Lymphocyte function-associated antigen-1 
mAb  Monoclonal antibody  
MALDI-TOF Matrix assisted laser desorption/ionisation - Time of flight 
MBP  Myelin basic protein 
MOG  Myelin oligodendrocyte glycoprotein 
MRI  Magnetic resonance imaging 
MS  Multiple Sclerosis 
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NB  Neuroborreliosis 
OCB  Oligoclonal bands 
Osp  Outer surface protein  
PCR  Polymerase chain reaction 
RT  Reverse transcription 
RR-MS Relapsing- Remitting Multiple Sclerosis 
SA   Streptavidin 
SC  Single cell 
SP-MS Secondary progressive Multiple Sclerosis 
SSPE  Subacute sclerosing panencephalitis 
Tp  Treponema pallidum 
VZV  Varizella- Zoster-Virus 
V  Variable  
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